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Abstract

GLIAL CELL MODULATORS AND ASSOCIATED ANTI-INFLAMMATORY ACTIVITY:
IMPLICATIONS IN REDUCING METHAMPHETAMINE ABUSE-RELATED BEHAVIORS IN
RODENTS
By Sarah E. Snider
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2014
Advisor: Patrick M. Beardsley, Ph.D.
Professor of Pharmacology and Toxicology
Methamphetamine is a psychomotor stimulant that produces hyperactivity and euphoria and can
lead to drug-seeking and abuse. An estimate from 2005 put the cost of methamphetamine
abuse to society at an estimated 23.4 billion dollars. One of methamphetamine's effects is
activation of glial cells and associated neuroinflammatory activity in the periphery and CNS.
Glia are responsible for maintaining calcium homeostasis, neuroplasticity, immune activity, and
cell signaling. Activation of glia and neuroinflammation are becoming recognized as links in drug
abuse-related behavior. The goal of the present work was to assess the ability of ibudilast,
AV1013, and minocycline, three glial cell modulating compounds, to attenuate responding in
rodent procedures that model different aspects of methamphetamine abuse-related behavior.
First, Ibudilast (1.8, 7.5, 13 mg/kg) and AV1013 (10, 30, 56 mg/kg) were examined for their
effects on methamphetamine-induced (3 mg/kg) locomotor activity and sensitization in mice, the
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latter thought to involve neurocircuitry common with drug relapse. Ibudilast and AV1013 dosedependently attenuated methamphetamine-induced locomotor activity and its sensitization.
Second, ibudilast (1, 7.5, 10 mg/kg), AV1013 (1, 10, 30 mg/kg), and minocycline (10, 30, 60
mg/kg) were examined for their effects on methamphetamine self-administration (0.001, 0.03,
and 0.1 mg/kg/inf) in rats. All three compounds significantly reduced methamphetamine (0.03
mg/kg/inf) self-administration. Results suggested baseline self-administration rate as a possible
determinant of these effects; however, follow-up tests with ibudilast while controlling for baseline
response rate dismissed this possibility. Additional follow-up tests identified whether the
attenuation of operant response rates was specific to methamphetamine-maintained behavior.
Using a behavioral economic approach, all three test compounds were determined to also affect
non-nutritive banana pellet-maintained responding when the baseline strengths maintained by
methamphetamine and banana pellet delivery were matched. Finally, ibudilast was evaluated
for its effects on methamphetamine discrimination in rats, a procedure thought to model clinical
subjective effects. Ibudilast (1, 7.5, 10 mg/kg) did not significantly modify methamphetamine’s
discriminative stimulus effects when trained at either 1 or 0.56 mg/kg. These results support the
hypothesis that attenuation of glial cell activity and neuroinflammation may be linked to some
abuse-related behaviors of methamphetamine, reinforcing their examination as novel targets for
treating methamphetamine abuse.

Chapter I: INTRODUCTION

Background and Significance
Methamphetamine abuse
Methamphetamine is a psychomotor stimulant and is classified as a Schedule II
controlled substance in the United States (Control, 2012). Methamphetamine abuse is
widespread and detrimental to both society and the individual. In 2010, amphetamine type
stimulant abuse prevalence was ranked second only to cannabis worldwide with an estimated
14.3 to 52.5 million users (Crime, 2012). Methamphetamine use continues to be consistently
high in Asia and the market for methamphetamine is increasing in parts of Europe (Norway,
Germany, Sweden, Finland, and other Scandinavian countries) (Crime, 2012). Although
estimates for current users in the United States were down from 731,000 in 2006 to 353,000 in
2010, there still were approximately 105,000 young users who reportedly tried
methamphetamine for the first time (SAMHSA, 2010). Additionally, with the increase in
methamphetamine seizures in the US, new methods for methamphetamine production by
clandestine laboratories has been increasing rapidly (Crime, 2012). Geographically,
methamphetamine abuse in the US is most prevalent in the western states in country/farm
1

regions (Johnston, 2011), whereas methamphetamine clandestine laboratory incidents almost
exclusively occur in Midwestern states (i.e. Kentucky, Tennessee, Missouri, Indiana) (DEA,
2012). In 2005, methamphetamine abuse cost society an estimated 23.4 billion dollars, largely
due to premature death and productivity losses, drug treatment and health care, criminal justice,
and cleanup of toxic chemicals from methamphetamine production (Nicosia et al., 2009;
Watanabe-Galloway et al., 2009)
Centrally, methamphetamine increases motor activity, libido, alertness, and feelings of
euphoria (Peachey et al., 1976; MacKenzie & Heischober, 1997; Winslow et al., 2007) by
interacting with the monoaminergic dopamine, serotonin, and norepinephrine neurotransmitter
systems (Creese, 1983; Cho & Segal, 1994). Peripherally, dopaminergic, alpha- and betaadrenergic stimulation leads to increased heart rate, blood pressure, force contraction, and
arterial and venous vasoconstriction (Lynch & House, 1992; MacKenzie & Heischober, 1997).
The perceived positive effects of elevated mood states and increased physical output, can lead
to drug-seeking and chronic abuse (Everitt & Robbins, 2005; Vanderschuren & Everitt, 2005).
Chronic methamphetamine abuse is associated with a range of centrally and peripherally
mediated toxicities (Lynch & House, 1992; Chuck et al., 1996; MacKenzie & Heischober, 1997;
Hamamoto & Rhodus, 2009).
Central nervous system (CNS) toxicity associated with chronic methamphetamine use
include agitation, insomnia, psychosis, paranoia, and visual and tactile hallucinations
(MacKenzie & Heischober, 1997). Also, the spontaneous recovery of methamphetamine
psychosis and paranoid hallucinatory states (i.e. flashbacks) in the absence of drug, can be
elicited by mild stressors and are associated with increased plasma norepinephrine levels
underscoring methamphetamine’s ability to sensitize noradrenergic hyperactivity (Yui et al.,
1997; Yui et al., 2000).
2

Peripherally, cardiac problems as a result of chronic methamphetamine abuse are wideranging. Dysrhythmias, myocardial infarcts, hypertension, congestive heart failure, vasculitis,
cardiomyopathy, and cardiac muscle lesions have all been cited as outcomes of chronic use
(Lynch & House, 1992; He et al., 1996). Dental disease is also a significant outcome, as
methamphetamine abusers commonly have tooth decay, wear from grinding, and decreased
salivary flow (Hamamoto & Rhodus, 2009). Interestingly, dental disease is not a product of
smoking the drug because intravenous methamphetamine users are more likely to have missing
teeth than users who smoked (Shetty et al., 2010). Corneal ulceration, known as keratitis, has
been associated with chronic methamphetamine usage as well (Chuck et al., 1996; Poulsen et
al., 1996). Finally, methamphetamine’s immune suppression peripherally increases abusers’
vulnerability to pathogens and infection (Harms et al., 2012). Methamphetamine-related
hepatitis has been reported although most cases of hepatitis observed in methamphetamine
users are contracted virally (Davis et al., 1970). Similarly, methamphetamine abuse has high
rates of co-morbidity with human immunodeficiency virus (HIV) and an exacerbation of its
effects, including increasing viral load and neurocognitive impairment (Carey et al., 2006;
Theodore et al., 2006; Toussi et al., 2009; Wang et al., 2012b; Wires et al., 2012; Blackstone et
al., 2013).
Methamphetamine-related deaths are most often caused by coronary heart disease and
subarachnoid hemorrhage (Karch et al., 1999), but may also be caused by seizure, stroke, liver
or lung disease (MacKenzie & Heischober, 1997; Karch et al., 1999). Thus, it is clear that
methamphetamine’s widespread abuse is costly to both society and to the user’s health
underscoring the need for a treatment approach for methamphetamine stimulant abuse.
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Current treatments
Some behavioral intervention programs can reduce methamphetamine abuse. The
Matrix Model integrates a variety of treatment approaches including individual therapy, relapse
prevention and family education groups, urine testing, and participation in a 12-step program
(Rawson et al., 1995) and is successful in reducing methamphetamine usage and sustaining
abstinence for up to two years (Obert et al., 2000). Contingency Management (CM) programs in
which the participant receives monetary or prize rewards for sustained abstinence also
decreases positive methamphetamine urine samples from methamphetamine abusers (Roll et
al., 2006). Furthermore, CM alone and in combination with cognitive behavioral therapy (CBT)
significantly reduces methamphetamine use and sexual behaviors in gay and bi-sexual men
when compared to standard CBT or gay-specific social support therapy alone (Shoptaw et al.,
2005; Shoptaw et al., 2008). Other interventions such as Acceptance and Commitment
Therapy, which emphasizes observation, thinking, and mindfulness/acceptance exercises, as
opposed to avoidance, reduce methamphetamine abuse to a similar degree as CBT (Smout et
al., 2010) and presenting repeated within-session multi-modal (picture, video, in-vivo) drugrelated cues diminish methamphetamine cue-elicited craving (Price et al., 2010). While these
treatments can be successful in time, they require individualized therapy and close monitoring
by the counselor as well as knowledgeable personnel and adequate funding (Rawson et al.,
2002; Kay-Lambkin, 2008). As such, discovering an effective pharmacotherapy to reduce
methamphetamine abuse may serve as a vital complement to behavioral interventions to
increase methamphetamine abstinence.
In order to identify potential targets for an effective pharmacotherapy, a close
examination of methamphetamine’s neurochemical effects is required. While most research
efforts have focused on targeting the bioamine receptors to develop pharmacotherapeutic
4

agents, for they are the direct mediators of methamphetamine's abuse-related effects (see
below), those efforts have not been successful (Karila et al., 2010). For instance, compounds
involving varied bioamine receptor activity such as bupropion, modafinil, and aripiprazole, have
had poor efficacy (Brackins et al., 2011). Thus, while an understanding of methamphetamine’s
classical neuro-receptor mechanisms is important, an expanded examination of its non-receptor
targets, such as the neuroglia, and how that interaction affects behavior may lead to fresh
approaches in drug development.

Methamphetamine’s Neurochemical Effects
Monoamines
Methamphetamine is best known for interacting with the monoaminergic dopamine,
serotonin, and norepinephrine neurotransmitter systems (Creese, 1983; Cho & Segal, 1994).
Amphetamine and methamphetamine work in several ways to increase the concentration of
monoamines in the synapse promoting increased signaling. First, amphetamines cause a
reversal of vesicular dopamine and monoamine transporter systems causing non-exocytotic (i.e.
calcium independent) efflux of dopamine and other monoamines out of vesicles and then out of
the cell (Liang & Rutledge, 1982; Creese, 1983; Cho & Segal, 1994; Brown et al., 2001; Schmitz
et al., 2001; Khoshbouei et al., 2003). Amphetamines also reduce dopamine transporter
function (Fleckenstein et al., 2000) and cause cell-surface dopamine transporter endocytosis,
likely through a clathrin-mediated pathway (Saunders et al., 2000), which impedes dopamine reuptake. Serotonin (5-HT) transporter function is rapidly decreased following acute
methamphetamine exposure as well, likely through a similar mechanism to dopamine
transporter down-regulation (Fleckenstein et al., 1999). Conversely, while the norepinephrine
5

transporter is structurally similar to the other two, it is less vulnerable to oxidative inactivation via
reactive oxygen species (Haughey et al., 1999); instead the norepinephrine transporter’s
reduction in re-uptake activity is a proposed to be a direct effect of methamphetamine’s (or its
metabolites’) action on the transporter itself (Haughey et al., 2000). However, the result is
similar in that there is decreased uptake.
Under normal physiological conditions, dopamine (D2) auto-receptors, located extrasynaptically, sense dopamine and its metabolites (i.e. DOPAC and homovanillic acid) and
decrease dopamine production and release (Cooper et al., 2003). Amphetamines interrupt this
negative feedback mechanism and enhance dopamine synthesis (Cooper et al., 2003).
Enhanced dopamine synthesis occurs via methamphetamine-induced increases in tyrosine
hydroxylase activity to promote the production of dopamine (Mandell & Morgan, 1970; Cooper
et al., 2003), while concurrently inhibiting monoamine oxidase (MAO), the enzyme that
degrades monoamines (Green & El Hait, 1980). Thus, methamphetamine’s neurochemical
actions promote the release of monoamines, prolong the time they are present in the synapse
by inhibiting re-uptake, and stimulate continued synthesis which results in increased excitation
and signaling.
Repeated administrations and/or high doses of methamphetamine are neurotoxic to the
same monoaminergic systems. At high doses, methamphetamine decreases tyrosine
hydroxylase and tryptophan hydroxylase activity, 5-HT concentrations, and dopamine and 5-HT
transporter function (Buening & Gibb, 1974; Hotchkiss et al., 1979), which is likely due to axonal
and/or terminal injury (Kogan et al., 1976; Fleckenstein et al., 2000). While the primary
mechanism of methamphetamine-induced neurotoxicity is still unclear, the presence of
excessive cytoplasmic and extracellular dopamine levels appears to be necessary to induce
neurotoxicity (Wagner et al., 1983). Dopamine metabolism produces reactive oxygen species
6

and dopamine quinones which can cause detrimental effects to the nerve terminals (Cadet &
Brannock, 1998; Yamamoto & Zhu, 1998), inactivate the dopamine transporters (Fleckenstein et
al., 2000), and induce distinct behavioral responses (Kita et al., 2009). Oxidative inactivation of
transporters and subsequent nerve injury is also exacerbated by methamphetamine-induced
hyperthermic effects produced by the drug alone and in conjunction with environmental
conditions like ambient temperature (Fleckenstein et al., 2000; Kiyatkin & Sharma, 2012). In
sum, methamphetamine causes a profound effect on the monoaminergic system both acutely
and chronically, and following repeated or high dose administration methamphetamine can
cause severe terminal damage and neurotoxicity.
While most pharmacotherapeutic approaches have focused on these direct mechanisms
affecting bioamine receptor activity, methamphetamine also has additional, less understood,
neurochemical effects including those on intracellular cAMP levels and of glial cell activation
that have both been suggested to play a role in modulating methamphetamine-induced
behavior.
Cyclic adenosine monophosphate (cAMP, cyclic AMP or 3'-5'-cyclic adenosine
monophosphate)
Methamphetamine-induced increases in synapse monoamine neurotransmitters lead to
dopamine D1 receptor (D1R) and D2 receptor (D2R) activation. D1R activation is associated
with an increase in adenylyl cyclase activity, which catalyzes the conversion of ATP to cAMP,
producing a subsequent increase in cAMP levels; whereas, activation of D2R is associated with
a decrease in cAMP (Kebabian et al., 1984). As cAMP is a second messenger molecule, these
alterations in cAMP levels may lead to modulations of downstream signal transmission and
behavioral effects. Although the activation of the two dopamine receptors work in apparently
7

opposing directions, it has been hypothesized that activation of both D1R and D2R are required
to produce methamphetamine sensitization and reinforcing effects (Kelly et al., 2008).
Specifically, with an increase in cAMP levels (through D1R), cAMP-dependent protein
kinase (PKA) phosphorylates dopamine- and cAMP-regulated neuronal phosphoprotein
(DARPP-32) at one of several phosphorylation sites (Hemmings et al., 1984) . Phosphorylation
of DARPP-32 at the Thr34 residue converts DARPP-32 into a potent inhibitor of another protein
inhibitor, protein phosphatase-1 (PP-1) (Hemmings et al., 1984). Phosphorylated Thr34DARPP-32 dependent signaling is associated with modulating many drug-induced actions
including behavioral responses mediated through the dopaminergic pathways (Svenningsson et
al., 2005). For example, DARPP-32 knockout mice have an attenuated response to
amphetamine-induced increases in repetitive movements and pre-pulse inhibition
(Svenningsson et al., 2003) suggesting that DARPP-32 is partially responsible for these
behaviors. Interestingly, acute administration of amphetamine upregulates Thr34-DARPP-32
phosphorylation (Svenningsson et al., 2003), while repeated administration of
methamphetamine produces sensitization and a decrease in Thr34-DARPP-32 phosphorylation
(Chen & Chen, 2005; Borgkvist & Fisone, 2007). Methamphetamine also induces an increase
in the phosphorylation of the transcription factor cAMP response element-binding protein
(CREB). While CREB plays several roles in behavioral activity as well, an enhancement of
CREB seems to play a protective role against addiction-like behaviors (Carlezon et al., 2005).
For example, cocaine-induced up-regulation of CREB in the nucleus accumbens is suggested to
counter-act the primary effects of cocaine and limit sensitization (Carlezon et al., 2005; Dong et
al., 2006).
Because PP-1, the enzyme inhibited by phosphorylated Thr34-DARPP-32, inhibits
CREB, Thr-34-DARPP-32 and CREB seem to be linked. Furthermore, the previously mentioned
8

studies showing a decrease in Thr34-DARPP-32 phosphorylation following methamphetamine
sensitization are consistent with CREB’s protective activity role. That is, with repeated
administration of methamphetamine, the decrease in phosphorylated Thr34 DARPP-32
increases PP-1 inhibition activity, thus decreasing CREB’s protective activity to counter-act
sensitization.
While the D2R works in the opposite direction at adenylyl cyclase to decrease cAMP
concentration, D2R stimulation also leads to activation of phospholipase Cβ (PLCβ) via its
coupling to Gq protein (Yan et al., 1999). PLC promotes the production of IP3 which in turn
releases Ca+2 stores (Yan et al., 1999; Hernandez-Lopez et al., 2000) to excite downstream
targets, suggesting a mechanism for D2R activation to affect behavioral activity.
Finally, D1R and D2R activation are both necessary to alter synaptic plasticity in the
striatum which can affect behavioral outcomes such as locomotor activity (Calabresi et al.,
1992; Pollack, 2004). In fact, heteromerization of D1R and D2R has been shown to lead to the
activation of Gq protein, PLC, and IP3 inducing a Ca+2 signal (Hasbi et al., 2010). Ca+2
signaling activates CaMKII in the rat striatum contributing to synaptic plasticity (Rashid et al.,
2007), and potentiating amphetamine self-administration (Loweth et al., 2008). Interestingly,
psychostimulants’ up-regulation of medium spiney neuron spine density in the nucleus
accumbens is more stable and sustained longer in the D1 receptors over the D2 receptors (Lee
et al., 2006) implying the downstream effects of D1 activation may be longer lasting. Thus,
modulation of cAMP levels may be sufficient to attenuate methamphetamine-induced abuse-like
behaviors through D1’s DARPP-32 and CREB protective actions.
In addition to its effects on cAMP, methamphetamine also induces glial cell activation
and pro-inflammatory responses.

9

Glial Cells
While neuroinflammation is commonly associated with neurodegenerative conditions,
decades of evidence indicate that some CNS-active drugs can induce neuroinflammatory
processes via activation of glial cells as well. Glial cells can be separated into two main groups,
macroglia and microglia. One sub-type of macroglia, astrocytes, are the most prevalent cell type
in the CNS and have a variety of functions including the response to injury by stimulating proinflammatory cytokine release and immune function activity (Benveniste, 1992). Microglia work
as macrophages to degrade foreign debris and are also associated with immune response by
responding to and secreting inflammatory cytokines (Benveniste, 1992). Following
methamphetamine administration, activated microglia and astrocytes release pro-inflammatory
cytokines (Yamaguchi et al., 1991; Nakajima et al., 2004a; Goncalves et al., 2008; Loftis et al.,
2011). Methamphetamine increases levels of cytokines and inflammatory factors, such as tumor
necrosis factor (TNFα), interleukin 6 (IL-6), interleukin 1β (IL-1β) mRNA levels, monocyte
chemo-attractant protein 1 (MCP-1), and cellular adhesion molecule (ICAM-1) (Yamaguchi et
al., 1991; Nakajima et al., 2004b; Goncalves et al., 2008).
How methamphetamine promotes neuroinflammation is not yet known. As mentioned
above, dopamine quinones and reactive oxygen species contribute to methamphetamineinduced cellular damage and apoptosis (Fleckenstein et al., 1997; Zhu et al., 2006). As a result
of the damaged cells and neurotoxicity, astrocytes and microglia become activated and elicit an
immune response and increase pro-inflammatory cytokine production (Kita et al., 2008; Clark et
al., 2012). Environmental factors such as ambient temperature and hyperthermic state of the
subject can exacerbate the methamphetamine-induced effects of glial activation and damage to
the blood-brain barrier (Kiyatkin & Sharma, 2012; Kousik et al., 2012).
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While cell damage and death is a common catalyst for inflammation induction,
methamphetamine’s effects on inflammatory pathways can also temporally occur before
dopamine cell terminal pathology (LaVoie et al., 2004). Thus, methamphetamine-induced
inflammation can occur at non-neurotoxic levels and independently of cell damage. A
mechanism has been proposed for methamphetamine-induced inflammation via the nuclear
transcription factor kappa-light-chain-enhancer of activated B cells (NF-κB) (Shah et al., 2012).
Methamphetamine’s release of excitatory neurotransmitters activates the metabotropic
glutamate receptor, mGluR5. The mGluR5 receptor is described to activate the intracellular
signaling pathway, AKT/PI3K, that downstream induces the release of NF-κB, which, in turn,
translocates to the nucleus to promote transcription of inflammatory cytokine proteins such as
TNFα, IL-6 and IL-8 (Shah et al., 2012).
Interestingly, cAMP levels also modulate microglial cell activation (Ghosh et al., 2012),
and glutamate derived from glial cells preferentially can act on NMDA extrasynaptic receptors to
de-phosphorylate CREB and inhibit its protective action (Hardingham et al., 2002). These
reports indicate the potential for these two methamphetamine-induced mechanisms (i.e. glial
cell activation and cAMP modulation) to be associated with one another providing our first links
among cAMP, glial cell signaling, and drug abuse behavior (D'Ascenzo et al., 2007).
In sum, methamphetamine’s effects on classic neuronal signaling systems has been well
defined, however, methamphetamine also causes other neurochemical effects including those
on cAMP and glial cell activation. While the importance of glial cells in the CNS may have been
initially overlooked by the scientific community, there is recent evidence to suggest that glia and
their activation play a significant role in neurotransmission and drug-induced behavior.
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Importance of Glia
Nervenkitt or neuroglia, literally “nerve-glue” in English, were merely considered
connective tissue that served only as scaffolding between neurons when first identified in the
early 1900s (Somjen, 1988). However, in the 1980s one subtype of glial cells, astrocytes, were
shown to exhibit voltage-gated channels and neurotransmitter receptors leading to increased
interest in their function (Volterra & Meldolesi, 2005). Glial cells, specifically astrocytes and
microglia, are now described as having a significant role in homeostatic processes,
synaptogenesis and guiding neuronal development, neuroplasticity, and regulating the immune
responses in the CNS by releasing pro-inflammatory cytokines and chemokines (Volterra &
Meldolesi, 2005). Glial cells can elicit their own signals, termed gliotransmission, and regulate
synapse formation and strength via the release of pro-inflammatory cytokines by astrocytes and
microglia (Lawrence et al., 2007). Activated glial cells have been correlated with altering
synaptic transmission and drug abuse behavior (Haydon et al., 2009) and an examination of
glial cell function should highlight the importance of glial cell activity in behavior and suggest a
unique target for novel drug abuse pharmacotherapies.
Gliotransmission
Glial cells can elicit both excitatory and inhibitory signals, known as gliotransmission,
giving rise to the idea of the tripartite synapse (Araque et al., 1999) in which neurotransmitters
released from the pre-synaptic neuron not only bind and affect the post-synaptic neuron, but
also glial cells, which in turn can release their own gliotransmitters or neutralize synaptic
neurotransmitters. First, glial cells are activated as they exhibit many ionic and metabotropic
receptor complexes on their membranes such as those for norepinephrine, glutamate, GABA,
acetylcholine, histamine, adenosine, and ATP (Haydon & Carmignoto, 2006). They do not
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produce action potentials, but rather signal via oscillations in intracellular Ca+2 (Volterra &
Meldolesi, 2005). Following activation, glial cells may also release neurotransmitters, known as
gliotransmitters, glutamate, D-serine, and ATP which may modulate synaptic transmission and
neuronal excitability (Haydon & Carmignoto, 2006). For example, release of glutamate from
glial cells can excite glutamatergic NMDA and AMPA receptors on the post-synaptic neuron
(Haydon & Carmignoto, 2006; Eroglu & Barres, 2010). Furthermore, glial cells also play an
active role in maintaining the extracellular glutamate concentration to prevent excitotoxicity to
the neurons (Barbour et al., 1988). Thus, neurotransmitter signaling is no longer isolated to
neuronal receptors. Further, as a function of chronic gliotransmission signaling, glial cells also
have the capability to modulate synapses.
Regulation of synaptic strength by cytokines
The main processes thought to regulate synaptic plasticity are the cell surface delivery
and retention of the glutamatergic receptors, NMDA and AMPA (Eroglu & Barres, 2010).
Interestingly, an up-regulation of the pro-inflammatory cytokine tumor necrosis factor (TNFα)
elicited from activated astrocytes increases the expression of AMPA receptors on the cell
surface and increases NMDA receptor and AMPA receptor mediated synaptic currents (Beattie
et al., 2002; Stellwagen & Malenka, 2006) which subsequently improves synaptic efficacy and
signal strength. Conversely, the blockade of TNFα and an increase in brain-derived
neurotrophic factor (BDNF) will have the opposite effect (Beattie et al., 2002). A prolonged
change in this synaptic regulation is known as synaptic scaling which involves changes in the
synaptic strength based on activity levels. Importantly, these mechanisms in which
AMPA/NMDA ratios induce synaptic plasticity are important because they are associated with
stimulant-induced behavioral responses such as sensitization (Wolf, 1998).
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Thus, glial cells are capable of much more than providing scaffolding and debris
removal. Activated glial cells may transmit their own signals as well as regulate synaptic
strength suggesting that the innate immune system can modulate behaviors that define
addiction (Crews et al., 2011). While methamphetamine’s effects on glial cells were mentioned
above, it is not the only drug of abuse that does affect the glia.
Effects of other drugs on glia
Of the 12 most widely recognized classes of abused drugs worldwide, half can be
categorized as producing an anti-inflammatory and the other half an inflammatory profile in the
CNS (see Table 1). Inflammation is operationally defined here as the induction of CNS
microglial and/or astrocyte activation as well as the production and release of pro-inflammatory
cytokines or chemokines. While it cannot be concluded that neuroinflammation is a global
indicator of drug abuse behavior, an in depth examination of the mechanism by which these
drugs affect glial activity may reveal a pattern and potentially a mechanistic target.
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Table 1. Effects of common abused drugs on glial cell activity and inflammatory markers
Drug of Abuse

Effect on Glial Cells

Cytokines/Chemokines Affected

Inflammatory
Methamphetamine

MDMA

Morphine

Increases
astrocyte/microglia
activation
(Orio et al., 2004; Gekker et
al., 2006; Bruce-Keller et
al., 2008; Kita et al., 2008;
Sharma & Ali, 2008; Yao et
al., 2010; Clark et al., 2012;
Zhang et al., 2012; Frau et
al., 2013)

Cocaine

Ethanol

PCP

Increases astrocyte
activation
(Miguel-Hidalgo, 2005;
2006)
Induces microglia (only
because high doses are
neurotoxic)
(Nakki et al., 1996a;
Fattorini et al., 2008)

↑ TNF-a, IL-6, IL-1b, MCP-1, ICAM-1
↓ IL-2, IFN-y
(Yamaguchi et al., 1991; Nakajima et
al., 2004b; Goncalves et al., 2008;
Loftis et al., 2011)
↑ IL-1b
(Thomas et al., 2004b; Orio et al.,
2010)
↑ TNFa, IL-1b
LPS-induced ↑ in TNFa, IL-6, iNOS,
and NO
(Sawaya et al., 2009; Berta et al.,
2012; Chen et al., 2012)
↑ TNFa, IL-6, IL-1b, MCP-1
↓IL-10
(Gan et al., 1999; Lin et al., 2011;
Fox et al., 2012)
↑ TNFa, IL-6, IL-1b, MCP-1, IFN-y,
TGF-b, IL-8, IL-10, IL-12, iNOS,
COX2
(Blanco et al., 2004; Laso et al.,
2007; He & Crews, 2008)
↓ GDNF in dependent users
(Heberlein et al., 2010)
↑ TNFa (with non-toxic PCP doses)
(Paterson et al., 2006)

Anti-inflammatory

THC
LSD

Activates CB2 receptors on
microglia
(Puffenbarger et al., 2000;
Chung et al., 2011)
Suppresses proliferation of
B-and T-lymphocytes
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↓ LPS-induced TNFa, IL-6, IL-1b,
IL-1a
(Puffenbarger et al., 2000)
↓ IL-2, IL-4, IL-6
(House et al., 1994)

(House et al., 1994; Yu et
al., 2008)
Benzodiazepines

Nicotine

Decreases proliferation of
activated microglia
Increases neuroprotection
(Wilms et al., 2003)
Inhibits microglial and
astrocyte activation and
inflammation
Increases neuroprotection
(Ohnishi et al., 2009; Liu et
al., 2012b)

↓ TNFa and iNOS
(De Simone et al., 2005; Ohnishi et
al., 2009)

↓ TNFa mRNA
(Yang et al., 2007)

Pentobarbital

Caffeine

↓ TNFa and NO
(Wilms et al., 2003)

Inhibits LPS- and ageinginduced microglia activation
(Brothers et al., 2010)
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Anti-inflammatory Drugs of Abuse
Δ9-tetrahydrocannabinol (THC)
THC, an agonist at CB1 and CB2 receptors, has several reported anti-inflammatory
mechanisms. CB1 and CB2 receptor activation both work to reduce inflammation. A specific
CB1 agonist (WIN55, 212-2) protects against MPTP-induced dopamine neurotoxicity, microglial
activation, cytokine release, and oxidative damage (Chung et al., 2011) and CB2 receptors on
microglia inhibit inflammatory processes downstream (Puffenbarger et al., 2000). THC can also
bind to peroxisome proliferated activated receptor (PPAR) receptors, nuclear receptors which
act as transcription factors to affect gene expression which could potentially affect inflammation
(Granja et al., 2012). Agonists of PPAR-y reduce lipopolysaccharide (LPS)-induced microglial
activation, cytokine, and prostaglandin E2 (PGE2) release that would activate astrocytes for a
secondary reaction (Granja et al., 2012). Furthermore, THC can directly affect transcription
factors and genes, such as STAT1, STAT3, and Socs3 to cause even more anti-inflammatory
signal (Kozela et al., 2010). Finally, because THC is highly lipophilic, THC is hypothesized to
inhibit LPS-induced inflammation and cytokine release by disrupting the plasma membrane
fluidity and thereby inhibiting the activation of TLR-4 receptor by LPS (Puffenbarger et al.,
2000). Thus, THC’s anti-inflammatory activity is multi-modal and works at several levels of the
cell to inhibit the glial activation.
Nicotine
Nicotine’s effects are also anti-inflammatory. Nicotine decreases immune cell responses
both peripherally and centrally (Shi et al., 2009). Peripherally, nicotine decreases inflammation
by altering the activity of T-cells (Shi et al., 2009). Centrally, neurons, astrocytes, and microglia
have all been shown to exhibit nicotinic acetylcholine receptors (Shi et al., 2009), and activation
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by nicotine can suppress TNFα production by microglia and exert a neuroprotective role against
thrombin cytotoxicity (Ohnishi et al., 2009). Similarly, nicotine pretreatment significantly
suppresses LPS-induced microglial activation and TNFα mRNA expression in vivo and in vitro
through α7 nicotinic receptors and protects dopamine neurons (De Simone et al., 2005; Park et
al., 2007). Nicotine also suppresses LPS and MPP+- induced astrocyte activation in vitro via a
reduction in TNFα release, extracellular regulated kinase 1/2 (Erk1/2) and p38 activation (Liu et
al., 2012b).
As far as mechanism, nicotine is proposed to attenuate CNS inflammation by reducing
NF-κB and c-myc activation by inhibiting MAP kinases through the α7 nAChR (Liu et al., 2007),
and that stimulation of the α7 nAChR is necessary for the inhibition of astrocytes and
inflammation by cholinergic agonists (Liu et al., 2012b).
Benzodiazepines
The translocator protein (18 kDa)(TSPO), also known as peripheral benzodiazepine
receptor, is present in the CNS and its expression increases upon injury or inflammation (Chen
& Guilarte, 2008). Specific ligands for TSPO (Ro-5-4864 and R-PK11195) increase reactive
oxygen species (ROS) and IL-1β production, however both ligands inhibit ATP-induced
inflammation indicating that TSPO ligands have anti-inflammatory properties in the presence of
activated microglia (Choi et al., 2011). Bezodiazepines bind to TSPO and decrease the
proliferation of activated microglia, the release of NO, and TNFα in vitro which is thought to also
increase neuroprotection (Wilms et al., 2003).
Barbiturates
While there is an apparent absence of reports regarding the barbiturates’ direct effects
on astrocytes and microglia activation, pentobarbital has been shown to suppress TNFα mRNA
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expression in vivo and protect cells from TNFα-induced apoptosis in vitro (Yang et al., 2007).
Additionally, thiopental inhibits NF-kB by suppressing IkB kinase activity (Loop et al., 2003),
however the “thio” group (sulfur atom at the C2 position) was likely a structural requirement for
NF-kB inhibition (Loop et al., 2003) qualifying the potential for a common effect among all
barbiturates.
Lysergic acid diethylamide (LSD)
As a strong partial agonist at the 5-HT2A receptor, LSD suppresses proliferation of Blymphocytes, production of IL-2, IL-4, and IL-6 cytokines, and the induction of cytotoxic Tlymphocytes in vitro (House et al., 1994). Similarly, activating the 5-HT2A receptor with the
receptor-specific agonist, (R)-1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane ((R)-DOI)
inhibits TNFα and its pro-inflammatory markers ICAM-1, VCAM-1, IL-6, NO synthase, and NFκB (Yu et al., 2008) indicating that 5-HT2A receptors are involved in an anti-inflammatory
response. However, these reports are limited to peripheral inflammation, and LSD has not yet
been linked to microglial or neuroinflammatory signaling.
Caffeine
Caffeine antagonizes both the adenosine A1 and A2A receptors pre-synaptically, which
increases glutamate signaling (Solinas et al., 2002), and attenuates LPS- and aging-induced
microglial activation (Brothers et al., 2010). Caffeine enhances astrocyte and microglial
reactivity following exposure to MDMA, however it was proposed that the gliosis was likely due
to hyperthermia as a result of MDMA neurotoxicity that was exacerbated by caffeine (Khairnar
et al., 2010).
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In sum, while it seems THC, nicotine, benzodiazepines, barbiturates, LSD, and caffeine
all exhibit some anti-inflammatory effects and most attenuate glial activation, there is currently
not a common mechanism by which these drugs work. Conversely, there are a number of
drugs that cause inflammatory effects similar to methamphetamine’s effects on glial cells.
Inflammatory Drugs of Abuse
The following drugs of abuse all exhibit neuroinflammatory profiles as reported in the
literature, and the body of evidence to support the hypothesis that glial cell activation and
inflammation play a role in addiction-like behaviors is growing rapidly (Miguel-Hidalgo, 2009;
Coller & Hutchinson, 2012). Thus, an examination of the effects on CNS inflammation induced
by these drugs, as well as the potential mechanisms involved, may provide insight for common
targets for potential pharmacotherapies.
MDMA (3, 4-methylenedioxy-N-methylamphetamine)
MDMA induces microglial activation and the release of IL-1β (Orio et al., 2004; Thomas
et al., 2004a; Orio et al., 2010; Frau et al., 2013). MDMA has also been shown to induce
astrocyte activation, however, this was only after MDMA first induced hyperthermia, cellular
injury, and disruption of the blood-brain barrier (BBB), suggesting that astrocyte activation is a
consequence of earlier MDMA induced toxic events (Sharma & Ali, 2008). Conversely, while
microglial activation was correlated with MDMA hyperthermia (Frau et al., 2013), it was not
dependent upon it, indicating independent mechanisms (Orio et al., 2004).
MDMA’s potential mechanism may be linked to the A2A adenosine receptor system. The
A2A receptor antagonist, SCH 58261, attenuates MDMA-induced increases in NF-κB mRNA and
protein levels (Kermanian et al., 2013) indicating an anti-inflammatory effect. Furthermore, A2A
receptor knock-out mice exhibit decreases in microglial and astrocyte activation following
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MDMA administration and less MDMA self-administration compared to their wild-type littermates
(Ruiz-Medina et al., 2011). Interestingly, CB1 and CB2 receptor systems have also been shown
to modulate MDMA-induced microglia and astrocytes and protect against MDMA neurotoxicity.
For example, a CB2 agonist as well as THC significantly inhibits MDMA-induced microglial
activation and IL-1β release (Torres et al., 2010; Tourino et al., 2010). THC’s neuroprotective
role against MDMA requires both CB1 and CB2 receptors to be present (Tourino et al., 2010),
as CB1 receptors attenuate MDMA hyperthermia and CB2 receptors attenuate the inflammatory
response (Tourino et al., 2010).
Phencyclidine (PCP)
Acute, non-neurotoxic doses of PCP produce a regionally specific (prefrontal cortex
only) decrease in TNFα levels (Paterson et al., 2006). In contrast, high doses of ketamine (80
mg/kg), PCP (10 and 50 mg/kg), and MK-801 (5-10 mg/kg) all induce microglial activation,
however this effect is likely due to neuronal injury, damage, and cell death (Nakki et al., 1995;
Nakki et al., 1996b; Nakki et al., 1996c). Glutamatergic NMDA receptors are present on
microglial cells and which can be activated with kainic acid (Eriksson et al., 2000). Further, the
resulting cytokine mRNA production may be attenuated by MK-801 (Eriksson et al., 2000)
suggesting that NMDA receptor activation may be an important player in glial cell activation and
inflammatory actvity.
Ethanol
Chronic ethanol up-regulates iNOS, COX2, and IL-1β in cultured astrocytes, and upregulates NF-κB and AP-1 signaling (Blanco et al., 2004; Valles et al., 2004). In humans,
ethanol produces increases in IL-1β, IL-6, TNFα, and IFN-γ cytokine levels (Laso et al., 2007),
and elevation of MCP-1 levels in the VTA, substantia nigra, hippocampus, and amygdala were
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found in post-mortem alcoholics’ brain tissue (He & Crews, 2008) indicative of increased proinflammatory signaling. Alcohol’s major metabolite, acetaldehyde, also induces NF-κB mediated
IL-1β and TNFα expression indicating that the pro-inflammatory response is most likely a
combined effect of ethanol and its metabolites (Hsiang et al., 2005). Furthermore, serum levels
of the neurotrophic factor GDNF are decreased in alcohol dependent subjects (Heberlein et al.,
2010), reducing neuroprotection.
While ethanol withdrawal increases astrocyte proliferation in the prefrontal cortex
(Miguel-Hidalgo, 2005; 2006), some neuroprotective factors are also up-regulated. In humans
GDNF and BDNF serum levels become escalated in early withdrawal and are associated with
lower withdrawal scores and lower alcohol tolerance scores (Heberlein et al., 2010) indicative of
some recovery.
Ethanol-induced inflammatory signaling in astrocytes is a consequence of up-regulating
p65 activity, a transcription factor involved in the NF-κB signaling pathway (Davis & Syapin,
2004). Ethanol also activates the TLR4 receptor by inducing its translocation to lipid rafts in
astrocytes, which enhances the same NF-κB signaling pathway downstream (Blanco & Guerri,
2007; Szabo et al., 2007; Blanco et al., 2008). In microglia, ethanol induces this activation and
translocation of TLR4 as well as TLR2 receptors to lipid rafts (Fernandez-Lizarbe et al., 2013).
The hetero-dimerization of TLR4 to TLR2 potentiates ethanol’s inflammatory effect (FernandezLizarbe et al., 2013) suggesting that microglia enhance the inflammatory signal induced by
astrocytes.
Finally, LPS-induced inflammation, via TLR4 receptor activation, increases alcohol
consumption in mice (Blednov et al., 2011). Genetic knockouts of the TLR4 receptor, on the
other hand, are protected against ethanol-induced inflammation, locomotor activity, memory and
anxiety, and epigenetic changes (Pascual et al., 2011), indicating that the TLR4 receptor and its
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downstream signaling pathways are vital components of ethanol’s inflammatory and behavioral
effects.
Cocaine
Cocaine’s inflammatory profile does not seem to be nearly as extensive as the other
drugs of abuse. Cocaine up-regulates IL-1β from astrocytes, IL-6, and TNFα expression, and
down-regulates IL-10 (Gan et al., 1999; Cearley et al., 2011; Lin et al., 2011; Fox et al., 2012).
Cocaine also increases BBB permeability, enhancing monocyte migration across the barrier
inducing ICAM-1 and VCAM-1 expression (Fiala et al., 1998). Cocaine’s induction of MCP-1
and enhancement of HIV are regulated through the sigma-1 receptor which is present on
microglia (Gekker et al., 2006; Yao et al., 2010). Also, withdrawal from cocaine has an effect on
astrocytes themselves as suggested by the induction of GFAP following three weeks of
abstinence, indicative of astroglial plasticity (Bowers & Kalivas, 2003).
Mechanistically, there is no direct evidence linking cocaine’s effect on glial cells or
inflammation and the TLR4 receptor as with alcohol and morphine. However, chronic cocaine
increases NF-κB induction in the nucleus accumbens (Ang et al., 2001) and has been
implicated in playing a direct role in cocaine’s abuse and sensitization by inducing increases in
dendritic spine densities to alter neuronal plasticity (Russo et al., 2009). Another proposed
mechanism for cocaine’s effect on glial cells involves the glutamatergic systems. mGluR5
receptors, which are present on astrocytes, become activated by extracellular glutamate
released by cocaine administration. Then, astrocytes generate Ca+2 signaling cascades
inducing a prolonged stimulus associated with selectively activated NR2B-containing
extrasynaptic neuronal NMDA receptors (D'Ascenzo et al., 2007; Fellin et al., 2007) implicating
gliotransmission’s role in altering cocaine-induced behaviors. Furthermore, mice lacking the
mGluR5 gene do not exhibit cocaine-induced locomotor activity increases nor do they reliably
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self-administer cocaine (Chiamulera et al., 2001). Interestingly, the activation of astrocytic
mGluR5 receptors and of NF-kB pathways is similar to the proposed mechanism of
methamphetamine’s action and it is linked to abuse-like behaviors.
Morphine
Similar in breadth to methamphetamine's neuroinflammatory activity, morphine activates
astrocytes and microglia and up-regulates the production of many pro-inflammatory cytokines in
the CNS (Bruce-Keller et al., 2008; Zhang et al., 2012). Morphine up-regulates cytokines such
as TNF-α, IL-1β, IL-6 mRNA levels in the nucleus accumbens, medial pre-frontal cortex, and
dorsal root ganglia (Sawaya et al., 2009; Berta et al., 2012; Chen et al., 2012) and increases
LPS-induced expression of the same cytokines via the mu opioid receptor located on microglial
cells and the protein kinase C (PKC) pathway (Merighi et al., 2013). Furthermore, one of
morphine’s metabolite’s, morphine-3-glucoronide, activates TLR4 and causes microglial
activation and the release of IL-1β (Lewis et al., 2010) indicating that opioids’ metabolites
contribute to their inflammatory action as well.
Mechanistically, similar to ethanol, morphine has been suggested to require TLR2
receptors for its inflammatory action, as TLR2 receptor knock-out mice do not exhibit morphineinduced microglial activation, cytokine release, and have attenuated morphine withdrawal
symptoms relative to wild types (Zhang et al., 2011). Also, a study utilizing a small interfering
RNA (siRNA) directed against p65, an element of the NF-kB signaling pathway, indicated that
morphine-induced TNFα release was NF-κB pathway dependent (Sawaya et al., 2009).
Activation of the PKC pathway stimulates AKT upstream of ERK 1/2 and iNOS (Merighi et al.,
2013) which is the same AKT pathway that stimulates NF-kB induction in the proposed
mechanism of methamphetamine-induced glial cell activation (Shah et al., 2012; see
discussion). Interestingly, CB2 receptor activation attenuates morphine-induced inflammation by
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interfering with the AKT-ERK 1/2 pathway suggesting that activation of CB2, and the inhibition
of microglial activation and subsequent downstream inflammatory effects, may increase the
clinical efficacy of opioids (Merighi et al., 2013).
Also similar to methamphetamine’s effects, opioids are also involved in increasing the
phosphorylation of DARPP-32 and DARPP-32’s link to behavioral effects and synaptic plasticity
(Mahajan et al., 2009). Finally, morphine’s glial cell activation and pro-inflammatory action is
also associated with its behavioral effects. Astrocyte-conditioned medium (i.e. activated
astrocytes) increases morphine-induced CPP when injected into the nucleus accumbens (Narita
et al., 2006).
In sum, the drugs of abuse that have exhibited neuroinflammatory profiles share some
aspects of their proposed mechanisms of action. For example, both ethanol and morphine have
been shown to require both TLR2 and TLR4 receptor activation to induce NF-kB to promote
cytokine production (Zhang et al., 2011; Fernandez-Lizarbe et al., 2013), and cocaine,
morphine, and methamphetamine have all been linked to activation of mGluR5 receptor and
AKT pathway activation to induce NF-kB (D'Ascenzo et al., 2007; Shah et al., 2012; Merighi et
al., 2013). Thus, perhaps a common mechanism of action preludes a common mechanistic
target for attenuating the downstream effects of these drugs and the behaviors they induce.

Novel approaches to attenuate drug abuse-like behavior
As mentioned above, methamphetamine’s regulation of cAMP levels in the brain are
implicated in mediating many of its behavioral effects such as methamphetamine-induced
hyperactivity, sensitization, and drug discrimination. Phosphodiesterase (PDE) degrades cAMP
(Beavo, 1995); so compounds that block PDE, will increase cAMP levels and could,
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consequentially, cause a change in methamphetamine-induced behaviors. Rolipram (a PDE
inhibitor) increases cAMP levels in the brain and dose dependently attenuates
methamphetamine-induced hyperlocomotion (Iyo et al., 1995; Iyo et al., 1996a; Iyo et al., 1996b;
Mori et al., 2000). In addition, rolipram and nifiracetam (another PDE inhibitor) attenuate
methamphetamine discrimination in mice (Yan et al., 2004; Yan et al., 2006). Thus, compounds
that influence cAMP levels may be potential methamphetamine pharmacotherapies that should
be tested in animal models. Methamphetamine also influences glial cells, suggesting another
therapeutic target.
Glial cell attenuating compounds have been shown to prevent increases or cause
decreases in up-regulated cytokines and chemokines in brain regions associated with opioid
withdrawal such as the ventral tagmental area and nucleus accumbens (Hutchinson et al.,
2009a), block morphine-induced CPP (Narita et al., 2006; Hutchinson et al., 2009a; Hutchinson
et al., 2009b), and block morphine and oxycodone spontaneous and precipitated withdrawal
signs (Hutchinson et al., 2009a). Developing evidence indicates that attenuating glial activation
can reduce methamphetamine-induced behavioral effects (Narita et al., 2006; Zhang et al.,
2006; Fujita et al., 2012). Correspondingly, an enhancement of neuroprotective growth factors,
like glial cell derived neurotrophic factor (GDNF), blocks cocaine (Green-Sadan et al., 2003;
Green-Sadan et al., 2005) and methamphetamine self-administration and vulnerability towards
reinstatement and sensitization (Niwa et al., 2007c; Yan et al., 2007) and attenuates morphine
CPP and morphine sensitization (Niwa et al., 2007a; Niwa et al., 2007b).
Finally, the initial component of methamphetamine’s proposed mechanism of glial cell
activation is the activation of the mGluR5 receptor. Activation of mGluR5 receptors, which are
present on glial cells (Miller et al., 1995), can lead to inflammatory downstream processes
(Shah et al., 2012), while mGluR5 antagonism attenuates on-going cocaine and
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methamphetamine self-administration as well as cue-and drug-induced reinstatement
(Chiamulera et al., 2001; Gass et al., 2009). Thus, both PDE inhibition, up-regulation of
neuroprotective neurotrophic factors, and anti-inflammatory activity all attenuate
methamphetamine-induced abuse-like behaviors.
Compounds of Interest
Ibudilast (AV411)
Ibudilast (3-isobutyryl-2-isopropylpyrazolo-[1, 5-a] pyridine) is a pyrazole-pyridine small
molecule which has a broad range of functions. Ibudilast is approved clinically to treat asthma
and post-stroke dizziness in Japan and is well tolerated in humans (Rolan et al., 2008; Rolan et
al., 2009). Ibudilast is a non-selective phosphodiesterase (PDE) inhibitor for PDEs 3, 4, 10, and
11 (Kishi et al., 2001; Gibson et al., 2006) and is a glial cell modulator and anti-inflammatory
agent which attenuates LPS-induced nitric oxide release, reactive oxygen species, TNF-a, IL1b, and IL-6 production (Suzumura et al., 1999; Mizuno et al., 2004; Rolan et al., 2009).
Ibudilast is also a potent inhibitor of macrophage migration inhibitory factor (MIF) (Cho et al.,
2010) and it attenuates LPS-induced microglial production of the chemokine MCP-1 (Ledeboer
et al., 2007).
Ibudilast enhances neuroprotective function by increasing the production of the antiinflammatory cytokine, IL-10, and neurotrophic factors such as GDNF, nerve growth factor
(NGF), and neurotrophin (NT-4) (Mizuno et al., 2004). Ibudilast is also neuroprotective against
glutamate toxicity by reducing Ca+2 influx (Tominaga et al., 1996). Separately, PDE inhibition
and glial cell modulation have already been reported to reduce drug abuse activity, as described
above. Thus, ibudilast’s effects could be a result of any or a combination of all these
mechanisms. Ibudilast has been reported to decrease opioid dependence and withdrawal signs
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(Ledeboer et al., 2007; Hutchinson et al., 2009a), attenuate morphine-induced dopamine
release in the nucleus accumbens (Bland et al., 2009), and CPP reinstatement in rats (Schwarz
et al., 2011). Importantly, ibudilast attenuates prime- and cue-induced reinstatement of
methamphetamine-maintained responding (Beardsley et al., 2010) further supporting the
hypothesis that PDE inhibition and/or glial cell modulation can alter methamphetamine-induce
behaviors.
AV1013
AV1013 ((R)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one
hydrochloride) is an amino analogue of ibudilast which exhibits similar glial attenuating actions
as ibudilast, but is impotent at inhibiting PDE (Cho et al., 2010). A characterization of AV1013’s
effects on methamphetamine-induced behaviors could suggest whether modulation of glial cell
activity is sufficient to have target effects without PDE inhibition.
Minocycline Hydrochloride
Minocycline (7-dimethylamino-6-dimethyl-6-deoxytetracycline), a second generation,
semi-synthetic tetracycline derivative, is indicated as a treatment for numerous infections due to
gram-positive and gram-negative micro-organisms including severe acne, some sexually
transmitted diseases, respiratory tract infections as well as some more serious conditions
including syphilis, anthrax, and plague (FDA, 2010). In addition to minocycline’s anti-microbial
action, its anti-inflammatory and neuroprotective functionality have implicated it as a potential
therapeutic for disorders including dermatitis, periodontal disease, rheumatoid arthritis, CNS
pathologies, neuropathic pain, inflammatory bowel disease, and allergic asthma (Garrido-Mesa
et al., 2013). Minocycline significantly attenuates microglial activation (Sriram et al., 2006;
Zhang et al., 2006) and suppresses LPS-induced TNFα, IL-6, IFN-γ and chemokines such as
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IL-8, MCP-1, and interferon inducible protein (IP)-10 via inhibition of IKKα/β phosphorylation, a
component of the NF-κB signaling cascade (Tai et al., 2013). Minocycline also attenuates the
biochemical effects of some drugs of abuse as it decreases NF-κB, IL-1β, and microglial
activation induced by MDMA (Orio et al., 2010) and significantly attenuates ethanol-induced upregulation of IκBα protein levels (Wu et al., 2011).
Minocycline attenuates drug-induced behavioral effects as well. Minocycline suppresses
methamphetamine and cocaine-induced hyperlocomotion and sensitization (Zhang et al., 2006;
Chen et al., 2009a) and prevents methamphetamine conditioned place preference (CPP) (Fujita
et al., 2012). Minocycline reduces morphine-induced respiratory suppression, attenuates
morphine CPP, enhances morphine analgesia (Hutchinson et al., 2008; Zhang et al., 2012),
attenuates tolerance to morphine analgesia (Cui et al., 2008) and decreases alcohol
consumption in mice (Agrawal et al., 2011). Finally, psychotic symptoms following
methamphetamine use are improved by minocycline in humans (Tanibuchi et al., 2010). Thus,
there is some previous evidence that PDE inhibition and glial cell modulation is related to drug
abuse-related behavior. Given that ibudilast, AV1013, and minocycline alter several of these
novel molecular targets, it is important to assess whether they could attenuate
methamphetamine induced abuse-like behaviors in several animal models of drug abuse.
Animal Models of Drug Abuse
There are a number of laboratory animal procedures that have face and/or predictive
validity for clinical drug abuse disorders that can be useful when evaluating potential
pharmacotherapies. While there is not one model that alone predicts drug abuse or its blockade
by a compound, studying the effects of compounds on several animals models of
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methamphetamine abuse provides a fuller profile of their ability to attenuate abuse-like
behaviors.
Locomotor Activity
First, methamphetamine, as a stimulant, elicits hyperactivity following administration
(Peachey et al., 1977). There are several ways to measure methamphetamine-induced
hyperactivity in rodents. Methods include recording stereotypies such as repeated rearing,
continuous sniffing or head bobbing, or tracking ambulatory behavior by measuring an animal’s
total distance traveled in an open field (Hall, 1934; Iyo et al., 1995; Kuribara, 1997; Buccafusco,
2001; Tatsuta et al., 2006). For example, acute methamphetamine-induces hyperactivity. When
wistar rats are administered 4 mg/kg methamphetamine (i.p.) it produces a significant increase
of distance traveled measured by almost 40,000 locomotor counts/hr compared to less than
300 counts/hr in the vehicle group (Iyo et al., 1995). Importantly, following repeated
methamphetamine administration its hyperlocomotion effect becomes more pronounced (i.e.
sensitized) (Nishikawa et al., 1983; Hirabayasi et al., 1991; Iyo et al., 1996b). For example,
animals challenged with 2 mg/kg methamphetamine following once-daily injections of 4 mg/kg
methamphetamine for 5 days show twice as great an increase in locomotor activity counts
compared to those who had received saline vehicle for the 5 days (Iyo et al., 1996a; Iyo et al.,
1996b).
Sensitization has been postulated to play a key role in drug addiction in humans
(Strakowski & Sax, 1998; Sax & Strakowski, 2001; Chen et al., 2009b), and the adaptations of
specific brain regions implicated in the process of sensitization have been associated with
reward pathways linked to drug-seeking and addiction (Robinson & Berridge, 1993).
Furthermore, sensitization phenomena interacts with similar neurocircuitry, neurotransmitter and
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receptor systems as those activated during reinstatement in models of drug abuse (Steketee &
Kalivas, 2011) implicating its association with craving and drug relapse. Thus, perhaps if
sensitization may be attenuated pharmacologically, the potential for relapse may been
attenuated as well. In sum, hyperactivity after acute methamphetamine administration and
sensitization after repeated administration can be modeled in rodents, and provide a valuable
tool for the study of drug addiction.
Self-administration
Drug use may be generated in laboratory animals using drug self-administration
procedures in which responses (such as lever pressing) result in drug administration (Schuster
& Thompson, 1969; Thompson & Pickens, 1970). Intravenous (i.v.) methamphetamine selfadministration in rats is well-established in our laboratory (e.g. Shelton & Beardsley, 2008;
Beardsley et al., 2010). Aside from the assay’s strong face validity for modeling drug-taking
behavior, self-administration procedures may be used to measure the ability of test compounds
to alter the reinforcing efficacy of an abused drug (Mello & Negus, 1996). In fact, several
compounds have been reported to reduce methamphetamine self-administration in rats (Ranaldi
& Poeggel, 2002; Neugebauer et al., 2007; Reichel et al., 2009). Thus, methamphetamine i.v.
self-administration is a well-established model of drug-taking behavior in rats, and should
provide a strong model of drug abuse-related behavior to test the effects of glial cell modulators.
Given the results obtained with self-administration studies alone, sometimes the
identification of the determinants and range of conditions for observing self-administration
effects is also important. Two potential variables that may influence the effects of test
compounds on drug self-administration are the response rate and response strength of the
drug-maintained baselines.
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Response Rate
Response rate dependency holds that a drug’s effects may differentially affect behavior
based on initial baseline rates of behavior. For example, Dews (1955) reported that a dose of
pentobarbital can increase low rates, but the same dose can decrease high rates of schedule
controlled behavior. Thus, a drug’s effect on behavior is a function of the control response rate.
A response rate control procedure controls for and determines whether a treatment compound’s
effects are rate dependent by maintaining the response rate for all conditions equal to determine
a change in behavior following test compound administration.
Behavioral Economics
The behavioral economic approach applies consumer demand theory to behavioral
psychology (Hursh, 1984). Consumer demand theory examines the relationship between price
and demand for a commodity, while behavioral economics examines the relationship between
an operant, such as lever presses, and total consumption of a reinforcer. The equation log Q=
log Q0 + k(e-αP – 1) developed by Hursh (1984) includes several variables, Q, Q0, k, P, and α,
used to generate a demand curve. Variable Q indicates total or normalized consumption of the
reinforcer, Q0 is consumption of the reinforcer when the price is set to zero, k is a constant that
specifies the range of the dependent variable in logarithmic units, P is the price of the
commodity, and α is a rate constant indicating the rate of change in elasticity of the demand
curve (Hursh & Silberberg, 2008). The demand curve itself indicates total consumption of a
particular reinforcer as a function of increasing price. The elasticity of the curve’s descent with
increasing price indicates the amount to which the subject will defend responding for the
particular reinforcer at higher prices (Hursh, 1984). Thus, when examining the demand curve for
a particular reinforcer, the rate of change in elasticity of the demand curve (α level) becomes an
important dependent variable. “Less elasticity”, and a small α level, can be interpreted as “more
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reinforcing” per this approach because consumption behavior continues even at high prices
(Hursh, 1984; Hursh & Winger, 1995; Hursh et al., 2005; Hursh & Silberberg, 2008). In order
measure and compare the reinforcing efficacy of several reinforcers to one another, the
behavioral economic approach engenders several advantages over response rate, behavioral
momentum, choice, and breakpoint methodologies.
Why behavioral economics?
In contrast to measuring response rates for a self-administration of a commodity to
assess its reinforcing strength, the dependent measure of behavioral economics is total
consumption. While response rate analyses are conventionally used in self-administration
studies, the inverted U-shaped curve in which response rates decline at higher doses of selfadministered drugs inhibits a comparison or reinforcing efficacies between different reinforcers
(Hursh et al., 2005). Furthermore, response rate measures are incapable of comparing
reinforcing strengths because the behavioral schedules and local contingencies set by the
experimenter can affect response rate responding (Hursh & Silberberg, 2008). There are other
approaches to measuring reinforcing strength. Behavioral momentum, the notion that the
relative strength of reinforcers may be measured by their relative resistance to change
responding following an experimenter-introduced disruption (Nevin, 1992), is again not
completely independent of schedule effects on rate of responding (Hursh & Silberberg, 2008).
Choice tasks maintain face-validity, but they are not independent of environmental factors such
as income and price (Hursh & Silberberg, 2008). Finally, many researchers employ progressive
ratio schedules to obtain a breakpoint measure of reinforcing strength. To obtain a breakpoint,
the ratio size incrementally increases with every reinforcer delivery during the session until the
subject no longer earns reinforcement. While breakpoints could be informative, they omit
information regarding behavior that occurs at different ratio sizes (Hursh & Silberberg, 2008),
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and the breakpoint may co-vary with experimenter set criteria (Stafford & Branch, 1998).
Breakpoints determined via within session progressive ratio tests are also vulnerable to satiation
effects (Giordano et al., 2001).
Hursh and others have effectively argued that traditional measures of reinforcement (i.e.
peak response rate, breakpoint, and preference) are all encompassed by and represented in
different portions of the demand curve (Bickel et al., 2000; Hursh & Silberberg, 2008) and that
measuring unit price is the most parsimonious method to studying reinforcing strength
(DeGrandpre et al., 1993). Thus, the demand curve and the behavioral economic approach is
currently the most appropriate method of comparing the reinforcing efficacy of different
reinforcers.
Drug Discrimination
Drug discrimination using laboratory animals is a procedure that is used to model the
subjective effects of a drug experienced by humans (Schuster, 1976; Brady & Balster, 1981). A
discrimination procedure reinforces a response dependent upon the stimulus conditions
prevailing during training sessions (Overton, 1979). In a drug discrimination procedure, the
discriminative stimuli are the interoceptive effects that occur following drug and saline
administration, and reinforcement is typically a food pellet delivery, access to sweetened milk, or
avoidance of shock reinforced by pressing a lever or a nose poke. The drug discrimination
procedure is viewed as a valuable method for studying the abuse liability of drugs of abuse
(Berkley & Stebbins, 1990) as it may be used to assess the extent to which a novel test drug
reproduces the "subjective effects" of a drug of abuse used as the training drug, or whether the
test drug attenuates those subjective effects when the two drugs are given concurrently
(Schuster, 1976; Solinas et al., 2006). Methamphetamine drug discrimination is well
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established, and methamphetamine is known to substitute for other stimulants such as
ephedrine, cocaine, methylphenidate, and d-amphetamine (Schechter, 1997b; Bondareva et al.,
2002; Sevak et al., 2009). In sum, a methamphetamine drug discrimination assay can determine
whether the interoceptive stimuli produced by methamphetamine administration are attenuated
when a potential pharmacotherapy is administered, and by inference, whether the subjective
effects of methamphetamine and the control they exert on behavior is weakened.
Rationale
Locomotor activity and its sensitization, self-administration, and drug discrimination each
are related to different aspects of drug abuse-like behavior as modeled in rodents. Thus,
utilizing all three of these assays in combination to assess the effects of the glial cell modulators
would help identify their effectiveness in attenuating different aspects of methamphetamine
abuse. First, examining effects on locomotor activity in mice allows for a measure of drug effects
on methamphetamine-induced acute hyperactivity and the development of sensitization, which
potentially tracks the effects of methamphetamine-induced synaptic plasticity as well as the
likelihood of relapse. Comparing ibudilast’s effects to those of AV1013 on methamphetamineinduced locomotor activity also helps identify whether glial cell modulation alone, without
inhibition of PDE, is sufficient to affect this behavior and its sensitization.
Second, assessing ibudilast, AV1013, and minocycline’s effects on self-administration
behavior in rats determines whether PDE inhibition and/or glial cell modulation can attenuate
on-going drug-taking behavior and again allows for a comparison between these drugs’ effects.
If the test compounds did effect on-going methamphetamine self-administration, identification of
the behavioral determinants and range of conditions for observing these effects would be
important. Two potential variables that may influence the effects of test compounds on drug self35

administration are the response rate and strength of the drug-maintained baselines. Controlling
for potential response rate determinants of ibudilast's effects is crucial to ensure that the drug’s
effects are not exclusively rate dependent. Behavioral economics can be used to help in the
evaluation of the non-specific effects of the test compounds, such as testing for reductions in
responding maintained by alternate reinforcers (i.e. food pellets) when baseline strength is
equated.
Finally, drug discrimination is thought to model the subjective effects of a drug. Thus,
evaluating a compound's effects on methamphetamine’s discriminative stimulus effects would
help identify the importance of its mechanism(s) as involved in occasioning episodes of drug
taking in human abusers. In summary, examining the test compounds ibudilast, AV1013, and
minocycline in these behavioral assays, accompanied by control procedures, clarify their ability
to attenuate different components of methamphetamine abuse-related behaviors, as well as the
underlying mechanisms of those behaviors.
Hypothesis
Previous literature suggests that inhibiting PDE function and modulating glial cell activity
can alter drug abuse-related behavior (Iyo et al., 1995; Yan et al., 2006; Miguel-Hidalgo, 2009;
Crews et al., 2011). Ibudilast, AV1013 and minocycline all modulate glial cell activation and
reduce inflammatory processes (Kishi et al., 2001; Mizuno et al., 2004; Cho et al., 2010; Tai et
al., 2013). Furthermore ibudilast and minocycline have been reported to attenuate some druginduced behavioral effects including those of methamphetamine (Zhang et al., 2006; Hutchinson
et al., 2009a; Beardsley et al., 2010; Agrawal et al., 2011; Schwarz et al., 2011; Fujita et al.,
2012). Thus, the present study hypothesizes that ibudilast, AV1013 and minocycline will
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attenuate the locomotor activity and sensitization, self-administration, and the discriminative
stimulus effects of methamphetamine.
Research Approach
1) Determine ibudilast and AV1013’s effects on the locomotor activity and its sensitization
induced by methamphetamine in mice
2) Evaluate ibudilast, AV1013, and minocycline’s ability to modulate methamphetamine
self-administration in rats
a. Control for rate-dependent effects
b. Control for methamphetamine-specific effects using a behavioral economic
approach
3) Determine if the discriminative stimulus effects of methamphetamine are modulated by
ibudilast
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Chapter II: The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate
methamphetamine locomotor activity and its sensitization in mice1

Introduction
This purpose of the following study was to examine the ability of ibudilast to attenuate
the acute and chronic effects of methamphetamine-induced hyperactivity and sensitization in
mice. Additionally, the amino analog of ibudilast, AV1013, which retains ibudilast's ability to
inhibit glial cell activation but has minimal PDE inhibitory effects (Cho et al., 2010), was also
tested to determine whether PDE inhibition was essential for the initial effects observed with
ibudilast.

Methods
Subjects
Male adult C57BL/6J mice were obtained at approximately 8 weeks of age (The Jackson
Laboratory, Bar Harbor, ME) and were allowed to acclimate to the vivarium for approximately
one week prior to commencement of testing. The mice were housed at a maximum of four per
1

Some content of Chapter II is adapted from Euro. J. Pharmacol, 2012, 679: 75-80
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cage in an Association for the Assessment and Accreditation of Laboratory Animal Care
(AAALAC) International-accredited animal facility with food (7012 Teklad LM-485 Mouse/Rat
Sterilizable Diet, Harlan Laboratories, Inc., Indianapolis, IN) and water available ad libitum under
a 12-h/12-h light/dark cycle (lights illuminated from 0600-h to 1800-h) with all testing occurring
during the light phase. All procedures were carried out in accordance with the “Guide for the
Care and Use of Laboratory Animals” (Institute of Laboratory Animal Resources, National
Academy Press, 1996) and were approved by the Institutional Animal Care and Use Committee
of Virginia Commonwealth University.
Apparatus
Locomotor activity tests were conducted in eight commercially obtained, automated
activity monitoring devices each enclosed in sound- and light-attenuating chambers that
recorded distance traveled in cm in 10-min bins via computer-controlled circuitry (AccuScan
Instruments, Columbus OH). The interior of each device was divided into separate 20 × 20 × 30
cm arenas permitting the independent and simultaneous measurement of two mice. Sixteen
photobeam sensors per axis were spaced 2.5 cm apart along the walls of the chamber and
were used to detect movement.
Locomotor activity procedure
One hundred and twenty-eight mice were randomly assigned into 16 groups of eight
mice each. Eight groups were treated b.i.d. for 7 days with subcutaneous (s.c.) injections of
either 0 (vehicle; VEH1), 1.8, 7.5, or 13 mg/kg ibudilast, with two groups of eight at each dose.
Eight other groups were similarly treated but with 0 (vehicle; VEH2), 10, 30, or 56 mg/kg
AV1013. Both ibudilast and AV1013 injections occurred twice daily separated approximately 7
hours apart (0900-h and 1600-h). During the last five days of these seven-day regimens (Days
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3–7), the mice were given locomotor activity tests. Two, 1-h locomotor activity sessions
(Baseline and Test) were given on Days 1 and 5. Single locomotor activity sessions were given
on Days 2–4 to minimize the occurrence of extinction of any conditioned locomotor activity
effects in methamphetamine treated mice. On days when locomotor activity sessions were
administered (Days 3–7), morning ibudilast and AV1013 injections were given 1 h prior to the
first session. Immediately prior to Baseline and Test sessions on Days 1 and 5, all mice were
injected intraperitoneally (i.p.) with saline or 3 mg/kg methamphetamine, respectively. On Days
2–4, half of all mice in the ibudilast and AV1013 groups received 3 mg/kg i.p. methamphetamine
(METH) before all locomotor activity sessions (IBUD + METH and AV1013 + METH groups),
while the other half received saline injections (IBUD + SAL and AV1013 + SAL groups). Thus,
the mice were distributed across groups as shown in Table 2 and treated as shown in Table 3.
Drugs
(±)-Methamphetamine (National Institute on Drug Abuse, Rockville, MD) was prepared in
0.9% saline stock solutions sterilized by filtration through 0.2 μm filtration disks. Working
methamphetamine solutions were dissolved in sterile 0.9% saline and injected i.p. Ibudilast (3isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) and AV1013 ((R)-2-amino-1-(2isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one hydrochloride) were received as a gift from
MediciNova, Inc., San Diego, CA). Ibudilast was prepared in 35% polyethylene glycol (PEG) in
saline vehicle and administered s.c. (referred to below as “VEH1”). Doses of AV1013 were
administered s.c. and prepared in sterile 0.9% saline (referred to below as “VEH2”), with the
exception of the highest dose (56 mg/kg) that was solubilized in a 35% PEG in saline vehicle
(i.e., VEH1) because of its incomplete dissolution in 0.9% saline. All injections were given in a
volume equivalent to 10 ml/kg body weight.
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Data analysis
Distance traveled (cm) was subjected to analysis by a mixed-model ANOVA (repeated
measures on Testday test and between comparisons on drug condition) for the chronically
administered methamphetamine and vehicle groups separately for each drug (i.e., 2 drugs × 2
methamphetamine treatment conditions = 4 ANOVAs). Comparisons between ibudilast or
AV1013-treated mice to their respective vehicle condition were made using Bonferroni Multiple
Comparisons Tests. AD50 (CI) values for attenuating methamphetamine hyperactivity by 50%
relative to vehicle controls were estimated by first converting distance traveled scores for each
mouse to percent of its respective mean vehicle control, logarithmically transforming dose, and
using nonlinear regression assuming a normalized response. All statistical tests were conducted
using computer software (Prism 5d for Macintosh, GraphPad Software, Inc., San Diego, CA),
and all types of comparisons were considered statistically significant if P < 0.05.

Results
Ibudilast and chronic methamphetamine
Fig. 1 shows the effects of ibudilast on chronic methamphetamine administration (upper
frame) and on chronic vehicle administration (lower frame). ANOVA results indicated that drug
[F (3, 28) = 7.093; p = 0.0011] and time [F (6,168) = 56.64; P < 0.0001] and their interaction [F
(18,168) = 2.479; p = 0.0013] significantly affected activity. Methamphetamine induced a
significant increase in total distance traveled of over 2900 cm during the Testday 1 test relative
to Baseline 1 levels in the VEH1 + METH group (t = 3.735, df = 7, P < 0.05) (Fig. 1, upper
frame; significance not indicated by asterisks). Methamphetamine also induced increases in
distance traveled during the Testday 1 test from Baseline 1 levels in the IBUD + METH treated
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groups, but their levels were non-significantly different, and increases were less than those of
the VEH1 + METH group. Distance traveled progressively increased in the VEH1 + METH
group following each subsequent day of methamphetamine administration and was significantly
(t = 4.325, df = 7, P < 0.01) greater during the Testday 5 test relative to the Testday 1 test
indicative of sensitization. Distance traveled on Testday 5 was significantly greater relative to
Testday 1 in the 1.8 IBUD + METH (t = 6.316, df = 7, P < 0.0001) and 7.5 IBUD + METH (t =
5.2000, df = 7, P < 0.0001) groups, but not the 13 IBUD + METH group, indicating that 13 mg/kg
ibudilast blocked the induction of sensitization. Ibudilast reduced distance traveled during all test
sessions following methamphetamine administration relative to the VEH1 + METH treatment
group, and significantly so during Testday 2–5 tests at 13 mg/kg ibudilast and during Testday 3
and 4 tests at 7.5 mg/kg ibudilast.
Ibudilast and acute methamphetamine
Distance traveled did not differ between the VEH1 + SAL group and any of the ibudilast
groups following saline administration indicating that ibudilast did not affect locomotor behavior
in mice without methamphetamine histories (Fig. 1, lower frame). However, ibudilast
significantly reduced distance traveled following methamphetamine administration during the
Testday 5 test, relative to the VEH1 + SAL group, at all doses of ibudilast (1.8 mg/kg ibudilast: t
= 3.278, df = 7, P < 0.05; 7.5 mg/kg ibudilast: t = 6.944, df = 7, P < 0.0001; 13 mg/kg ibudilast: t
= 6.374, df = 7, P < 0.0001) indicating its ability to blunt the acute challenge by
methamphetamine.
AV1013 and chronic methamphetamine
Fig. 2 shows the effects of AV1013 on chronic methamphetamine administration (upper
frame) and on chronic vehicle administration (lower frame). ANOVA indicated a significant effect
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of drug [F (4, 34) = 5.947; p = 0.0010], time [F (6,204) = 92.28; P < 0.0001, and their interaction
[F (24,204) = 2.282; p = 0.0010]. Methamphetamine induced a significant increase in total
distance traveled during the Testday 1 test relative to Baseline 1 levels in the VEH1 + METH
group (t = 4.341, df = 7, P < 0.001). Methamphetamine induced a non-significant mean increase
in total distance traveled in the VEH2 + METH group during the Testday 1 test relative to
Baseline 1 levels, which further increased to significant levels during Testday 2 tests (t = 4.530,
df = 7, P < 0.001) (Fig. 2, upper frame). Methamphetamine induced increases in total distance
traveled by all AV1013 treatment groups during the Testday 1 test relative to Baseline 1 levels;
however, these were non-significant increases and were always less than respective control
vehicle groups. Total distance traveled generally increased in all groups following each
subsequent day of methamphetamine administration and were significantly greater during the
Testday 5 test relative to the Testday 1 test in all chronically-treated methamphetamine groups
(VEH2 + METH: t = 4.181, df = 7, P < 0.001; VEH1 + METH: t = 5.027, df = 7, P < 0.001, 10
AV1013 + METH: t = 5.618, df = 7, P < 0.001; 30 AV1013 + METH: t = 8.095, df = 7, P < 0.001,
56 AV1013 + METH: t = 4.154, df = 7, P < 0.001). Total distance traveled was significantly
reduced following 56 mg/kg AV1013 administrations relative to its vehicle control group (VEH1 +
METH) following methamphetamine treatment on all days. (Testday 1: t = 3.357, df = 7, P <
0.01; Testday 2: t = 3.681, df = 7, P < 0.01; Testday 3: t = 5.089, df = 7, P < 0.001; Testday 4: t
= 5.434, df = 7, P < 0.001; Testday5: t = 4.009, df = 7, P < 0.01).
AV1013 and acute methamphetamine
Total distance traveled did not differ between the VEH2 + SAL group and either the 10
AV1013 + SAL or 30 AV1013 + SAL groups during all test sessions that were preceded by
saline administration, indicating that AV1013 did not affect locomotor behavior on its own (Fig.
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2, lower frame). Similarly, distance traveled did not differ between the VEH1 + SAL and 56
AV1013 + SAL group indicating that 56 mg/kg AV1013 did not affect locomotor behavior in mice
without a methamphetamine history. However, following methamphetamine challenge during
Testday 5 tests, 30 mg/kg AV1013 significantly reduced levels of total distance traveled relative
to its vehicle control group, VEH2 + SAL (t = 4.683, df = 7, P < 0.001), as did 56 mg/kg AV1013
relative to its vehicle control group, VEH1 + SAL (t = 4.900, df = 7, P < 0.001).
Ibudilast vs. AV1013
The AD50 (CI) for ibudilast to reduce the hyperactivity effects of acute
methamphetamine challenge on Testday 1 was 7.146 (3.763–13.57) mg/kg for groups
chronically-treated with methamphetamine. By Testday 5 the AD50 (CI) increased to 23.23
(9.660–55.86) mg/kg in these groups. In groups whose first exposure to methamphetamine was
on Testday 5, but which had received chronic ibudilast up to Testday 5, the AD50 (CI) was
7.092 (3.420–14.71) mg/kg. This AD50 value was non-significantly different from that on
Testday 1 in the chronically treated methamphetamine group (i.e., vs. 7.146 mg/kg).
AV1013 attenuated methamphetamine's effects with an AD50 (CI) of 43.88 (19.40–
99.27) mg/kg on Testday 1 that increased to 201.2 (51.49–786.0) mg/kg on Testday 5 in the
chronically treated methamphetamine groups. In groups whose first exposure to
methamphetamine was on Testday 5 but which had received chronic AV1013 up to Testday 5
the AD50 (CI) was 48.13 (19.05–121.7) mg/kg. This AD50 value was non-significantly different
from that on Testday 1 in the chronically treated methamphetamine group (i.e., vs. 43.88
mg/kg).
When compared to each other, ibudilast produced significantly lower AD50 values than
AV1013 on both Testday 1 [F(1,61) = 11.32; p = 0.0013] and on Testday 5 [F(1,61) = 6.978; p =
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0.0105] in groups chronically-treated with methamphetamine, as well when comparing groups
chronically-treated with saline and challenged for the first time on Testday 5 [F(1,62) = 10.90; p
= 0.0016].

Summary
Ibudilast dose-dependently reduced both chronically and acutely administered
methamphetamine-induced locomotor activity. Chronic treatment with methamphetamine
provided evidence of sensitization as subsequent administrations elicited greater increases in
distance traveled. The highest dose of ibudilast (13 mg/kg) tested significantly attenuated these
methamphetamine-induced sensitization effects. Ibudilast's analog, AV1013, which lacks its
potency for inhibiting PDE, but retains its ability to suppress activated glial activity, similarly
dose-dependently attenuated methamphetamine's chronic and acute locomotor activity effects,
but was ~ 6–9 fold less potent in doing so. These later observations suggest that the ability to
modulate glial activity is sufficient to attenuate methamphetamine's locomotor activity effects,
although PDE inhibition likely can additionally contribute if present.
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Table 2. Distribution of mice in chronically and acutely treated methamphetamine (METH)
groups.
Chronic METH

Acute METH
Ibudilast Groups

VEH1+METH

VEH1+SAL

1.8 IBUD+METH

1.8 IBUD+SAL

7.5 IBUD+METH

7.5 IBUD+SAL

13 IBUD+METH

13 IBUD+SAL
AV1013 Groups

VEH2+METH

VEH2+SAL

10 AV1013+METH

10 AV1013+SAL

30 AV1013+METH

30 AV1013+SAL

56 AV1013+METH

56 AV1013+SAL
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Table 3. Treatment procedures
Day 1

Day 2

Day 3

Day 4

Day 5

1

Chronic METH groups

Injection #1

Saline

Saline

Session

Baseline 1

Baseline 5

Injection #2

METH

METH

METH

METH

METH

Session

Test 1

Test 2

Test 3

Test 4

Test 5

2

Acute METH groups

Injection #1

Saline

Saline

Session

Baseline 1

Baseline 5

Injection #2

Saline

Saline

Saline

Saline

METH

Session

Test 1

Test 2

Test 3

Test 4

Test 5

1
2

Groups include: IBUD+METH, AV1013+METH, VEH1+METH, VEH2+METH
Groups include: IBUD+SAL, AV1013+SAL, VEH1+SAL, VEH2+SAL
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Chapter II: Figure Legends
Fig. 1. Upper frame: Results on distance traveled (cm) by mice treated b.i.d. for seven days with
ibudilast (IBUD) or its vehicle (VEH1), beginning two days before five days of treatment with 3
mg/kg methamphetamine. Ibudilast was administered at 1.8, 7.5, or 13 mg/kg. Data points
represent group means (± S.E.M.) obtained during 1-h experimental sessions. Filled data points
represent sessions preceded by 3 mg/kg i.p. methamphetamine injections. Unfilled data points
represent sessions preceded by i.p. saline injections. N = 8 for each treatment group. *P < 0.05
with respect to mice treated with ibudilast's vehicle. Lower frame: Results on distance traveled
(cm) by mice treated b.i.d. for seven days with ibudilast (IBUD) or its vehicle (VEH1), beginning
two days before four days of saline administration and acute treatment with 3 mg/kg
methamphetamine on the fifth day. Ibudilast was administered at 1.8, 7.5, or 13 mg/kg. Data
points represent group means (± S.E.M.) obtained during 1-h experimental sessions. Other
details are as in the upper frame.

Fig. 2. Upper frame: Results on distance traveled (cm) by mice treated b.i.d. for seven days with
AV1013 or its vehicle (VEH2 for 10 and 30 mg/kg and VEH1 for 56 mg/kg), beginning two days
before five days of treatment with 3 mg/kg methamphetamine. AV1013 was administered at 10,
30, or 56 mg/kg. *P < 0.05 with respect to mice treated with AV1013's vehicle. Other details are
as in Fig. 1. Lower frame: Results on distance traveled (cm) by mice treated b.i.d. for seven
days with AV1013 or its vehicle (VEH2 for 10 and 30 mg/kg and VEH1 for 56 mg/kg), beginning
two days before four days of saline administration and acute treatment with 3 mg/kg
methamphetamine on the fifth day. Other details are as in the upper frame.
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Figure 2.
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Chapter III: Glial cell modulators attenuate methamphetamine self-administration in the rat 2

Introduction
The purpose of this study was to ascertain the effects of ibudilast, AV1013, and
minocycline on on-going self-administration of methamphetamine in rats. It was previously
reported that ibudilast attenuates stress- and prime-induced methamphetamine reinstatement in
rats (Beardsley et al 2010), and the previously described locomotor activity study suggested that
glial cell modulation and anti-inflammatory action is sufficient to attenuate methamphetamine
locomotor activity in mice. Thus, it was hypothesized that ibudilast, AV1013, and minocycline,
another compound that attenuates microglial activation, would attenuate on-going
methamphetamine self-administration.

2

Some content of Chapter III is adapted from Eur. J. Pharmacol., 2013, 701: 124-130.
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Methods
Subjects
Adult male Long-Evans hooded rats (Harlan, Indianapolis, IN) weighing 275-300 g at the
start of studies were acclimated to the vivarium for at least one week prior to catheter
implantation. When not in testing, rats were individually housed in standard plastic rodent cages
in a temperature-controlled (22o C), AAALAC International-accredited facility in which they had
ad libitum access to water. The rats were allowed ad libitum rat chow (7012 Teklad LM-485
Mouse/Rat Sterilizable Diet, Harlan Laboratories, Inc., Indianapolis, IN) for at least one week
prior to commencement of training, after which they were maintained at 320 g by controlled
feedings given after experimental sessions or at a comparable time of day if not tested. The rats
were maintained on a reversed, 12 h/12 h light-dark cycle (0600-1800 h lights off) for the
duration of the experiment, and they were trained and tested during the dark segment of this
cycle.
All procedures were carried out in accordance with the “Guide for the Care and Use of
Laboratory Animals” (Institute of Laboratory Animal Resources, National Academy Press, 1996)
and were approved by the Institutional Animal Care and Use Committee of Virginia
Commonwealth University.
Infusion assembly system
Catheters were constructed from polyurethane tubing (Access Technologies, Skokie, IL;
0.044” O.D. X 0.025” I.D.). The proximal 3.2 cm of the catheter was tapered by stretching
following immersion in hot sesame oil. The catheters were prepared with a retaining cuff
approximately 3 cm from the proximal end of the catheter. A second larger retaining cuff was
positioned approximately 3.4 cm from the proximal end of the catheter. Mid-scapula cannula
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connectors were obtained from Plastics One (Roanoke, VA). The cannula connectors consisted
of a threaded plastic post through which passed an “L” shaped section of 22 gauge stainless
steel needle tubing. The lower surface of the plastic post was affixed to a 2 cm diameter disc of
Dacron mesh. During sessions the exposed threaded portion of the infusion cannula was
connected to an infusion tether consisting of a 35 cm length of 0.40 mm i.d. polypropylene
tubing encased within a 30 cm stainless steel spring to prevent damage. The upper portion of
the 0.40 polypropylene tubing was connected to a fluid swivel (Lomir Biomedical, Inc, Quebec,
Canada) that was, in turn, attached via 0.40 polypropylene tubing to the infusion syringe.
Surgical procedure
Following acclimation to the laboratory environment, indwelling venous catheters were
implanted into the right external jugular vein. Rats were administered 5 mg/kg carprofen s.c.
(Rimadyl, Pfizer Animal Health, New York, NY) before surgery. Surgical anesthesia was
induced with a combination of 50 mg/kg ketamine (KetaThesia, Butler Animal Health Supply,
Dublin, OH) and 8.7 mg/kg xylazine (X-Ject E, Butler Animal Health Supply, Dublin, OH). The
ventral neck area and back of the rat were shaved and wiped with povidone-iodine, 7.5%
(Betadine, Purdue Products L.P., Stamford, CT) and isopropyl alcohol. The rat was placed
ventral side down on the surgical table and a 3 cm incision was made 1 cm lateral from midscapula. A second 0.5 cm incision was then made mid-scapula. The rat was then placed dorsal
side down on the operating table and a 2.5 cm incision was made longitudinally through the skin
above the jugular area. The underlying fascia was bluntly dissected and the right external
jugular vein isolated and ligated. A small cut was made into the vein using an iris scissors and
the catheter was introduced into the vein and inserted up to the level of the larger retaining cuff.
The vein encircling the catheter between the two cuffs was then tied with silk suture. A second
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suture was then used to anchor the catheter to surrounding fascia. The distal end of the
catheter was passed subcutaneously and attached to the cannula connector that was then
inserted subcutaneously through the larger incision. The upper post portion of the cannula
connector exited through the smaller mid-scapula incision. All incisions were then sprayed with
a gentamicin sulfate/betamethasone valerate topical antibiotic (Betagen, Med-Pharmex, Inc.,
Pomona, CA) and the incisions were closed with Michel wound clips. Five mg/kg oral carprofen
(Rimadyl, Bio-Serv, Frenchtown, NJ) was administered 24 h after surgery, and 8 mg/kg oral
enrofloxacin (Baytril, Bio-Serv, Frenchtown, NJ) was administered daily for three days following
surgery.
Rats were allowed to recover from surgery for at least 5 days before self-administration
training began. Periodically throughout training, ketamine (5 mg/kg) (KetaThesia, Butler Animal
Health Supply, Dublin, OH) was infused through the catheters to determine patency as inferred
when immediate anesthesia was induced. Between sessions the catheters were flushed and
filled with 0.1 ml of a 25% glycerol (Acros, New Jersey)/75% sterile saline locking solution
containing: 250 units/ml heparin (Abraxis Pharmaceutical Products, Schaumburg, IL) and 250
mg/ml ticarcillin/9 mg/ml clavulanic acid (Timentin, GlaxoSmithKline, Research Triangle Park,
NC). If during the experiment a catheter was determined to be in-patent, the left external jugular
was then catheterized and the rat was returned to testing.
Apparatus
Commercially-obtained test chambers equipped with two retractable levers, a 5-w house
light, and a Sonalert tone generator (MED Associates, Inc., St. Albans, VT) were used.
Positioned above each lever was a white cue light. A syringe pump (Model PHS-100; MED
Associates, Inc., St. Albans, VT) when activated, delivered a 6-sec, 0.2 ml infusion. Recording
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of lever presses and activation of lights, shockers, pumps, and Sonalerts were accomplished by
a microcomputer, interface, and associated software (MED-PC IV, MED Associates, Inc., St.
Albans, VT).
Self-administration procedure
Methamphetamine self-administration training sessions were conducted seven days per
week for 2 h daily. Each response (fixed ratio 1, FR1) on the right-side lever resulted in delivery
of a 0.1 mg/kg methamphetamine infusion (0.2 ml/6 sec) followed by a 14-s timeout period. At
the start of an infusion the house light was extinguished, the Sonalert was sounded, and the
cue lights above each lever flashed at 3 Hz. The Sonalert and cue lights remained activated
during the 6-s infusion. Twenty seconds following the onset of the infusion the house light was
re-illuminated, and the opportunity to self-administer methamphetamine was again made
available (i.e., each methamphetamine infusion initiated a 20 s period during which lever
presses were recorded but were without scheduled consequences and further infusions could
not be obtained). Active (right-side) lever presses during the infusions as well as all inactive
(left-side) lever presses were recorded but were without scheduled consequences.
Training sessions occurred until stability criteria were met. Stability criteria were defined
in which during the first and last session of at least 3 consecutive sessions neither the highest
nor lowest number of infusions were obtained, and the number of infusions during each session
was ±20% from the mean. Following training, ibudilast (1, 7.5 and 10 mg/kg) or AV1013 (1, 10
and 30 mg/kg) was administered i.p. twice daily, or minocycline (10, 30 and 60 mg/kg) was
administered i.p. once daily, or their corresponding vehicles were administered for three
consecutive days during self-administration of each of three doses of methamphetamine (0.1,
0.03, and 0.001 mg/kg/inf). Thus, a total of nine consecutive days of b.i.d. or once daily dosing
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of vehicle or dose of test drug was necessary to complete testing at each self-administered
dose of methamphetamine. Between tests of vehicle or dose of test drug, rats were maintained
under 0.1 mg/kg methamphetamine self-administration conditions with i.p. injections of the test
drug’s vehicle until training criteria were once again met.
Rate Dependency Analysis
Preliminary results had indicated that ibudilast reduced response rates maintained by
0.03 mg/kg/inf but not by 0.1 mg/kg/inf methamphetamine. In order to determine if the higher
baseline response rates maintained by 0.03 mg/kg/inf methamphetamine were the sole
determinants for the greater ibudilast-induced response rate reductions, relative to those
maintained at 0.1 mg/kg/inf methamphetamine, response rates were matched across the two
methamphetamine doses. Fixed-ratio requirements reinforced by 0.1 mg/kg/inf
methamphetamine were increased to increase response rates, and ibudilast was then re-tested
at its most influential dose of 10 mg/kg. Rats were trained to self-administer 0.1 mg/kg/inf
methamphetamine reinforced according to a FR1 schedule, and they were required to complete
the previously described stability criteria before proceeding. The fixed ratio requirement was
then adjusted to between FR2- FR4 in individual rats in order to increase response rates
reinforced by 0.1 mg/kg/inf methamphetamine to approximate, as a group mean response rate,
those maintained by 0.03 mg/kg/inf methamphetamine. Once the response rates were stably
matched between 0.03 and 0.1 mg/kg/inf methamphetamine groups, ibudilast (10 mg/kg) or its
vehicle was then administered b.i.d. i.p. for three consecutive days. Between three-day sets of
testing, animals were returned to training conditions and were required to meet stability criteria
once again.
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Drugs
(±)-Methamphetamine hydrochloride (National Institute on Drug Abuse, Rockville, MD)
was prepared in sterile 0.9% saline. Methamphetamine stock solutions were sterilized by
filtration through 0.2 µm filtration disks. Heparin (5 units/ml) was additionally added to
methamphetamine and saline infusates. Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5a]pyridine) and AV1013 ((R)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one
hydrochloride) were received as a gift from MediciNova, Inc. (San Diego, CA) and were
dissolved in a 35% PEG400, 10% Cremophor® RH40 (BASF, Ludwigshafen, Germany)
aqueous vehicle. Minocycline hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in
saline and a few drops of 1 M hydrochloric acid. Immediately prior administration, the
minocycline solution was adjusted to pH 3-4 using a few drops of sodium hydroxide. Ibudilast,
AV1013, and minocycline were all administered i.p. in 1 ml/kg body weight volume, except for
60 mg/kg minocycline that was given at 2 ml/kg body weight volume due to insolubility at the
lower volume.
Data Analysis
The number of infusions obtained on the third (and final) day of testing at each condition
was used for data analysis because it was assumed it would most likely represent terminal
behavior. Numbers of infusions comparing methamphetamine dose to saline under vehicletreatment conditions were made with Dunnett’s Multiple Comparison posttests following a oneway within-subjects ANOVA to determine if a dose of methamphetamine served as a reinforcer.
Additionally, infusion numbers were analyzed using a two-way repeated measures ANOVA
(repeated measures on treatment dose and between comparisons on methamphetamine dose),
and comparisons of ibudilast, AV1013, or minocycline treatment on methamphetamine self58

administration were assessed using Bonferroni Multiple Comparisons tests. AD50 (CI) values
for attenuating methamphetamine self-administration by 50% relative to vehicle control
conditions were estimated by first converting total infusions obtained to percent of their
respective vehicle control infusions, logarithmically transforming dose, and using nonlinear
regression assuming a normalized response.
For Rate Dependency Analysis, "response rate" was defined as the: (number of presses
of the right-side lever - those occurring during time-out periods) ÷ (total session duration in sec cumulative duration of all time-out periods). Response rates maintained by 0.03 mg/kg/inf
methamphetamine at FR1 were considered matched to response rates for 0.1 mg/kg/inf
methamphetamine at FR2-4 when there were no significant differences between group mean
rates when compared by an unpaired t-test. During 10 mg/kg ibudilast and vehicle treatment,
response rates at 0.03 mg/kg/inf methamphetamine administration were compared to those at
0.1 mg/kg/inf methamphetamine using a two-way analysis of variance (ANOVA) with repeated
measures on ibudilast "dose" (i.e., 10 mg/kg or vehicle) followed by Sidak's Multiple
Comparisons tests.
All statistical tests were conducted using commercial computer software (Prism 5d for
Macintosh, GraphPad Software, Inc., San Diego, CA), and all types of comparisons were
considered statistically significant if p < 0.05.
Results
Figure 3 illustrates the effects of ibudilast on methamphetamine self-administration.
Under b.i.d. vehicle conditions, methamphetamine was self-administered characterized by an
inverted U-shaped curve relating infusion numbers to dose, and the one-way within-subjects
ANOVA on infusion numbers was significant [F (3, 15) =32.75; p<0.001]. Dunnett’s posttests
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revealed that infusions of 0.03 and 0.1 mg/kg/inf methamphetamine were self-administered
significantly greater than those of saline (p<0.05) indicating that these doses were serving as
positive reinforcers under baseline conditions.
There was a significant effect of methamphetamine dose [F (2, 27) =19.90; p= 0.0005]
and ibudilast dose [F (3, 27) =3.44; p=0.0308]. Ibudilast did not systematically affect the number
of 0.001 mg/kg methamphetamine infusions, which had not served as a positive reinforcer
under vehicle conditions, nor the number 0.1 mg/kg methamphetamine infusions, which did
serve as a positive reinforcer. At its two highest doses (7.5 and 10 mg/kg), ibudilast reduced the
number of 0.03 mg/kg methamphetamine infusions, the methamphetamine dose that had
maintained the greatest number of infusions above those of saline under baseline conditions,
and significantly so at the 10 mg/kg ibudilast dose (p<0.05).
Response Rate Dependency analysis indicated that group mean response rate
maintained by 0.03 mg/kg/inf methamphetamine at FR1 was not significantly different from the
group mean response rate maintained by 0.1 mg/kg/inf methamphetamine in the matched
response rate group (FR2-4) (t=0.1591, df=6, p=0.8788)(Fig. 4). Although 10 mg/kg ibudilast
reduced infusion levels of 0.03 mg/kg/inf methamphetamine relative to vehicle control (t=3.998,
df=6, p<0.05), and as described above, infusion rates of 0.01 mg/kg/inf methamphetamine in
the matched response rate group were unaffected (t=1.324, df=6, p>0.05).
Figure 5 shows AV1013’s effects on methamphetamine self-administration. Under b.i.d.
vehicle conditions, methamphetamine was self-administered characterized by an inverted Ushaped curve relating infusion numbers to dose. The one-way within subjects ANOVA on
infusion numbers was significant [F (3, 19) =214.9; p<0.0001]. Dunnett’s posttest results
indicated that 0.03 and 0.1 mg/kg/inf methamphetamine doses were self-administered

60

significantly above those of saline (p<0.05) indicating that these doses were serving as positive
reinforcers.
There was a significant effect of methamphetamine dose [F (2, 36) =62.59; p<0.0001]
and AV1013 dose [F (3, 36) =10.59; p<0.0001]. As with ibudilast, AV1013 did not
systematically affect the number of 0.001 mg/kg methamphetamine infusions, which had not
served as a positive reinforcer under vehicle conditions, nor the number 0.1 mg/kg
methamphetamine infusions, which had served as a positive reinforcer. AV1013 did, however,
significantly reduce the number of 0.03 mg/kg methamphetamine infusions at the 10 and 30
mg/kg AV1013 doses (p<0.05).
Minocycline’s effects on methamphetamine self-administration are shown in Figure 6.
During daily dosing conditions with minocycline’s vehicle (saline), methamphetamine selfadministration was characterized by an inverted U-shaped curve relating infusion numbers to
dose. The one-way ANOVA on infusion numbers was significant [F (3, 19) =34.07; p<0.0001].
Dunnett’s posttests indicated that the 0.03 mg/kg/inf methamphetamine dose (p<0.05), but
neither the 0.001 mg/kg/inf nor the 0.1 mg/kg/inf methamphetamine doses, were selfadministered significantly above those of saline (although the level of 0.1 mg/kg/inf
methamphetamine self-administration infusions was similar to those obtained under baseline
conditions during tests with ibudilast and AV1013, self-administered saline infusions were
greater during minocycline testing).
There was a significant effect of methamphetamine dose [F (2, 36) =23.09; p<0.0001]
and minocycline dose [F (3, 36) =6.907; p=0.0009]. Minocycline reduced infusion numbers of
0.03 mg/kg/inf methamphetamine, significantly so at the 60 mg/kg dose of minocycline (p<0.05),
while infusion numbers of other self-administered doses of methamphetamine were nonsystematically affected.
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The potency (AD50 value) relationship amongst the drugs for reducing total infusions
obtained during 0.03 mg/kg/inf methamphetamine self-administration differed [F(2,53)=7.909;
p=0.001], and resulted in ibudilast being the most potent, followed by AV1013, and then
minocycline with respective AD50 (CI) values of 10.67 (3.86-29.47), 60.80 (23.26-158.9) and
128.8 (57.14-290.3) mg/kg.

Summary
Methamphetamine was established as a positive reinforcer and was self-administered
under vehicle pretreatment conditions characterized by an inverted U-shaped curve relating
infusion numbers to dose, with significantly more methamphetamine infusions being obtained at
the intermediate dose (0.03 mg/kg/inf) during testing of all drugs, and at the highest dose (0.1
mg/kg/inf) during testing of ibudilast and AV1013, relative to those obtained of saline. Ibudilast
(10 mg/kg), AV1013 (10 and 30 mg/kg) and minocycline (60 mg/kg) significantly reduced total
0.03 mg/kg/inf methamphetamine infusions compared to vehicle pretreatment conditions. These
results suggest that modulating glial cell activity and consequent neuroinflammatory processes,
can, in turn, modulate abuse-related effects of methamphetamine.

Controlling for methamphetamine-specific effects
The purpose of this control study was to assess whether the test compounds' effects
were specific to attenuating methamphetamine-induced behaviors. Knowing the degree of
specificity of the effects of these glial modulators would better profile the freedom with which
they could be used therapeutically, without affecting other behaviors. Relaxed specificity
suggests that non-target behaviors could also be affected. Incomplete specificity, however,
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should not preclude a test compound as a possible therapeutic, just as a potential cancer
chemotherapeutic shouldn't be automatically excluded from clinical use if it affects some noncancerous cells in addition to cancerous cells. Ibudilast, AV1013, and minocycline all reduced
methamphetamine self-administration, however will these compounds reduce responding for
another reinforcer such as food? It was hypothesized that in order to properly determine a test
compound's effects on food- and drug-maintained behavior, that both food and
methamphetamine should first be matched in terms of their relative reinforcing strength,
otherwise effects might be seen on a weak baseline but not on a stronger baseline regardless if
food or drug was the maintaining event. In order to match food- and methamphetaminemaintained baselines, a behavioral economics approach was used to ensure similar demand
curves obtained by both reinforcers before testing. One assumption of a behavioral economic
approach is that demand is calculated when the commodity in question is only available during
the testing session, that is, provided within a closed economy (Hursh, 1984). Hursh (1984)
showed that demand for a commodity is more elastic if it is available at alternative times outside
the testing procedure, and in an open economy, as compared to a closed economy. Thus,
controlling for this variable was an important component to consider prior to testing with a foodlike reinforcer given animals must be maintained at healthy body weights throughout the study.
Thus, non-nutritive banana flavored cellulose pellets were the closest approximation to a foodlike reinforcer while avoiding open economy confounds during testing. Ibudilast, AV1013, and
minocycline's effects on methamphetamine and non-nutritive banana pellet-maintained
responding and consumption were then assessed under the conditions in which both reinforcers
were inferred to have equal reinforcing strength.
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Methods
Subjects
Adult male Long-Evans hooded rats (Harlan, Indianapolis, IN) with a history of
methamphetamine self-administration were allowed to acclimate to the vivarium for at least one
week before training began. When not in testing, rats were individually housed in standard
plastic rodent cages in a temperature-controlled (22°C), AAALAC International-accredited
facility in which they had ad libitum access to water. Rats were assigned to one of two groups,
to assess the demand for self-administration of either methamphetamine (METH group) or 45
mg calorie-free (non-nutritive) banana flavored cellulose pellets (TestDiet) (BANANA group).
METH rats were maintained at 320 g by controlled feedings of rat chow (7012 Teklad LM-485
Mouse/Rat Sterilizable Diet, Harlan Laboratories, Inc., Indianapolis, IN) after daily sessions.
Before training, BANANA rats were allowed ad libitum rat chow for at least six days in order to
calculate each individual’s free feeding body weight to be used throughout the study. BANANA
rats were then maintained at 85% of their own free feeding body weight for remainder of the
study. All rats were maintained on a reversed, 12 h/12 h light-dark cycle (0600-1800 h lights off)
for the duration of the experiment, and they were trained and tested during the dark segment of
this cycle. All procedures were carried out in accordance with the “Guide for the Care and Use
of Laboratory Animals” (Institute of Laboratory Animal Resources, National Academy Press,
1996) and were approved by the Institutional Animal Care and Use Committee of Virginia
Commonwealth University.
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Procedure
Methamphetamine training
Methamphetamine self-administration training sessions were conducted seven days per
week for 2 h daily. Each response (fixed ratio 1, FR1) on the right-side lever resulted in delivery
of a 0.1 mg/kg methamphetamine infusion (0.2 ml/6 sec) followed by a 14-s timeout period. At
the start of an infusion the house light was extinguished, the Sonalert was sounded, and the
cue lights above each lever flashed at 3 Hz. The Sonalert and cue lights remained activated
during the 6-s infusion. Twenty seconds following the onset of the infusion the house light was
re-illuminated, and the opportunity to self-administer methamphetamine was again made
available (i.e., each methamphetamine infusion initiated a 20-s period during which lever
presses were recorded but were without scheduled consequences and further infusions could
not be obtained). Active (right-side) lever presses during the infusions as well as all inactive
(left-side) lever presses were recorded but were without scheduled consequences. Training
sessions occurred until stability criteria were met. Stability criteria were defined in which during
the first and last session of3 consecutive sessions neither the highest nor lowest number of
infusions were obtained, and the number of infusions during each session was ±20% from the
mean.
BANANA pellet Training
Banana pellet training sessions occurred seven days a week for 15 min daily. Rats were
trained to respond on a fixed ratio 10 (FR10) schedule in which 10 consecutive left-lever
responses resulted in a banana pellet delivery. Non-nutritive banana flavored cellulose pellets
were used to best approximate a closed economy, in which the “food-like” reinforcer is only
available during the session and caloric value does not influence total consumption. During the
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session, the house light remained illuminated, and there were no scheduled light or tone stimuli
presentations during food delivery. All inactive (right-side) lever presses were recorded but were
without scheduled consequences. Because the subjects had a history of methamphetamine
self-administration in which the right lever was active and upon infusion delivery both a stimulus
light and tone were presented, the banana pellet protocol removed those stimuli and reversed
the active lever position in order to avoid any confounding environmental conditioning. Following
training, rats were required to meet stability criteria on a FR1 schedule for banana pellet
delivery. Stability criteria were defined as the first and last session of three consecutive sessions
had neither the highest nor lowest number of active lever responses, nor the number of
responses during each session was more than ±20% from the mean. Additionally, rats did not
always consume all of their earned banana pellets within the session so stability criteria were
only met if <3 banana pellets remained following each of the three consecutive sessions.
Demand curve analyses
Following training, demand curve analyses were obtained for 0.1 and 0.03 mg/kg/inf
methamphetamine and banana pellet self-administration. For each curve, the fixed ratio was
increased daily in the following progression 1,3,6,9,13,19,26,35,47,62,82,108…using the
formula (response ratio = [5e(injection number x j)] – 5, where j=0.26)) adapted from Richardson and
Roberts (1996). Sessions continued until responding at a particular FR decreased to below that
sufficient to earn a single reinforcer during the session. Rats were then returned to FR1, and
were required to meet stability criteria before progressing to the alternate methamphetamine
infusion dose or banana pellet administration.
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Methamphetamine-specific consumption effects analysis
BANANA group rats were maintained at 85% of their individual free feeding body weight
and were required to meet stability criteria at FR1 for banana pellet administration. Once
stability was reached, twice daily i.p. administration of ibudilast (10 mg/kg), AV1013 (10, 30
mg/kg) 1-h prior to testing or once daily i.p. administration of minocycline (10, 30, 60 mg/kg) 67min prior to testing or their respective vehicles for three consecutive days under a FR1
schedule. Minocycline was administered 67-min prior to the test session to allow for similar pretreatment, distribution, and absorption time to that of the self-administration tests. Between
three-day sets of testing, rats were returned to FR1 training conditions and required to meet
stability criteria.
Drugs
(±)-Methamphetamine hydrochloride (National Institute on Drug Abuse, Rockville, MD)
was prepared in sterile 0.9% saline. Methamphetamine stock solutions were sterilized by
filtration through 0.2 µm filtration disks. Ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine)
and AV1013 ((R)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one hydrochloride)
were received as a gift from MediciNova, Inc. (San Diego, CA) and were dissolved in a 35%
PEG400, 10% Cremophor® RH40 (BASF, Ludwigshafen, Germany) aqueous vehicle.
Minocycline hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in saline and a few
drops of 1 M hydrochloric acid. Immediately prior to administration, the minocycline solution was
adjusted to pH 3-4 using a few drops of sodium hydroxide. Ibudilast, AV1013, and minocycline
were all administered i.p. in 1 ml/kg body weight volume, except for 60 mg/kg minocycline that
was given at 2 ml/kg body weight volume due to insolubility at the lower volume. Of note, two
additional vehicles were tested during the minocycline banana pellet consumption assays.
Veh30, a few drops of 1M hydrochloric acid added to sterile water to produce a vehicle with
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equivalent pH to 30 mg/kg minocycline, and Veh60 similar vehicle to Veh30 which was
administered at 2 ml/kg injection volume to control for injection volume at 60 mg/kg minocycline
administration, were tested. Neither vehicle produced significantly different total banana pellet
consumption compared to sterile water vehicle, so data is not shown.
Data Analysis
Demand curves were generated using the formula log Q = log Q0 + k (e-αP – 1) from
(Hursh & Silberberg, 2008). Non-linear regression best fit values for the alpha level parameter
were compared between reinforcer types using an extra sum-of-squares F-test. When tested on
a FR1 schedule, total consumption of METH (0.3 mg/kg/inf) or BANANA pellets was normalized
by calculating the percentage of reinforcer consumption under test compound (ibudilast,
AV1013 or minocycline) treatment compared to total consumption under vehicle conditions.
Normalized consumption percentages were analyzed using a two-way repeated measures
ANOVA (repeated measures on treatment dose and between comparisons on reinforcer type),
and comparisons of ibudilast, AV1013, or minocycline treatment on consumption were assessed
using Bonferroni Multiple Comparisons tests.
Results
The α levels (95% CI), the behavioral economic variable indicative of reinforcing strength
of a particular commodity, for (0.03 and 0.1 mg/kg/inf) methamphetamine self-administration
and banana pellet-maintained responding were calculated as 0.00012 (0.000075-0.00016),
0.000076 (0.000061-0.000090), 0.00013 (0.00011-0.00015) respectively. When the α levels of
0.3 and 0.1 mg/kg/inf methamphetamine were compared, the α level obtained under 0.1
mg/kg/inf methamphetamine conditions was significantly lower [F (1, 101) = 5.2, p=0.0246]
indicating that under these conditions, 0.1 mg/kg/inf methamphetamine had a stronger
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reinforcing strength. When 0.3 mg/kg/inf methamphetamine and banana pellets were
compared, there was not a significant difference [F (1, 87) = 0.2, p=0.65] indicating that the
baseline reinforcing strength of these two reinforcers, obtained under the specified conditions,
was successfully matched (Fig. 7). Thus, all further methamphetamine demand analyses were
performed using 0.03 mg/kg/inf methamphetamine.
There was a significant effect of ibudilast treatment on normalized consumption [F (1, 7)
=30.26; p= 0.0009]. Bonferroni multiple comparison’s indicated that 10 mg/kg ibudilast treatment
significantly decreased normalized consumption of both 0.3 mg/kg methamphetamine selfadministration (p<0.05) and banana pellets (p<0.05) compared to vehicle (Fig 8).
AV1013’s treatment effect on normalized consumption of 0.03 mg/kg/inf
methamphetamine self-administration and banana pellets was significant [F (2, 12) =12.63;
p=0.0011]. Normalized consumption of 0.03 mg/kg/inf methamphetamine was significantly
reduced by 10 and 30 mg/kg AV1013 compared to vehicle conditions (p<0.05). Banana pellet
consumption, however, was only significantly decreased by 30 mg/kg AV1013 (p<0.05) (Fig. 9).
Figure 10 illustrates minocycline’s effects on the normalized consumption of
methamphetamine (0.03 mg/kg/inf) and banana pellet administration. There was a significant
main effect of reinforcer type [F (1, 8) =7.741; p=0.0238] and minocycline treatment on
consumption [F (3, 24) =12.76; p<0.0001]. Normalized consumption of 0.03 mg/kg/inf
methamphetamine was significantly reduced by 60 mg/kg minocycline (p<0.05) compared to
vehicle conditions. Bonferroni multiple comparison’s also indicated that normalized consumption
of banana pellets while the subjects were maintained at 85% of their free-feeding body weight
was significantly decreased by 30 and 60 mg/kg minocycline (p<0.05).
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Summary
In order to support whether ibudilast, AV1013, and minocycline’s effects on attenuating
methamphetamine-induced behaviors are methamphetamine specific, the effects of the test
compounds was measured on the total consumption of an alternative reinforcer, non-nutritive
banana flavored cellulose pellets. Using behavioral economics, demand curves were generated
for methamphetamine (0.03 mg/kg/inf) and banana flavored pellets when the subjects were
maintained at 85% of their free-feeding body weight. Under those conditions, the reinforcing
strength (α level) of the two different reinforcers was successfully matched. All three test
compounds, ibudilast, AV1013, and minocycline, significantly attenuated total consumption of
banana pellets at the same doses that attenuated methamphetamine self-administration with
the exception of 10 mg/kg AV1013. This suggests that perhaps the intermediate dose of
AV1013 (10 mg/kg) was specifically attenuating methamphetamine self-administration without
affecting consumption of a non-nutritive food-like reinforcer.
Controlling for differential drug effects on differing reinforcing baselines
An assumption was made prior to initiating the previous studies involving the behavioral
economic analysis of test drug effects on banana pellet and methamphetamine-maintained
responding that baseline strength could be a determinant of whether a test compound affected
responding or not. The assumption was that baselines maintained by very weak reinforcers
would be affected before baselines maintained by stronger reinforcers. The following study
attempted to provide a proof-of-concept to support this assumption. The present study
examined food-maintained behavior while its baseline strength (α level) was manipulated by
altering the subject’s percentage of free feeding body weight. Test compounds were then
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evaluated to assess the extent to which baseline strength (i.e., efficacy of the food reinforcers)
determined the magnitude of their effects.

Methods
Subjects
Adult male Long-Evans hooded rats (Harlan, Indianapolis, IN) with a history of
methamphetamine self-administration were allowed to acclimate to the vivarium for at least one
week before training began. When not in testing, rats were individually housed in standard
plastic rodent cages in a temperature-controlled (22°C), AAALAC International-accredited
facility in which they had ad libitum access to water. Before training, FOOD rats were allowed ad
libitum rat chow for at least six days in order to determine each individual’s free feeding body
weight to be used throughout the study. FOOD rats were then maintained at a percentage of
their own free feeding body weight for remainder of the study. All rats were maintained on a
reversed, 12 h/12 h light-dark cycle (0600-1800 h lights off) for the duration of the experiment,
and they were trained and tested during the dark phase of this cycle. All procedures were
carried out in accordance with the “Guide for the Care and Use of Laboratory Animals” (Institute
of Laboratory Animal Resources, National Academy Press, 1996) and were approved by the
Institutional Animal Care and Use Committee of Virginia Commonwealth University.
Procedure
Food Pellet Training
Food pellet training was identical to banana pellet training as described above in which
sessions occurred seven days a week for 15 min. Rats were trained to respond on a fixed ratio
10 (FR10) schedule in which 10 consecutive left-lever responses resulted in delivery of a 45 mg
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rodent purified diet dustless precision pellet (BioServ, Frenchtown, NJ). During the session, the
house light remained illuminated, and there were no scheduled light or tone stimuli
presentations during food delivery. Because the subjects had a history of methamphetamine
self-administration in which the right lever was active and upon infusion delivery both a stimulus
light and tone were presented, the present protocol removed those stimuli and reversed the
active lever position in order to avoid any confounding environmental conditioning. All inactive
(right-side) lever presses were recorded but were without scheduled consequences. Following
training, rats were required to meet stability criteria on a FR1 schedule for food pellet delivery.
Stability criteria were defined as the first and last session of three consecutive sessions had
neither the highest nor lowest number of active lever responses, nor the number of responses
during each session was more than ±20% from the mean.
Demand Curve Analyses
The percent of ad libitum body weight was adjusted to vary the reinforcing efficacy
(demand) of the food reinforcer. Rats were maintained at 85%, 90%, 100%, or 115% of their
initial individual free feeding body weight by controlled feedings of rat chow following each daily
session. Initial individual body weights were determined by averaging daily weights from six
consecutive days of ad libitum feeding prior to initiation of weight maintenance and test
sessions. Because Long-Evans hooded rats’ growth and body weight continues to increase over
time (Harlan Laboratories, 2006), maintaining the animals at 115% of their body weight was
possible in later studies to introduce an even further reduction in the strength for food demand.
Immediately following meeting criteria at FR1, the fixed ratio was increased daily in the following
progression 1,3,6,9,13,19,26,35,47,62,82,108…using the formula (response ratio = [5e(injection
number x j)

] – 5, where j=0.26)) adapted from Richardson and Roberts (1996). Sessions continued
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until responding at a particular FR decreased to below that sufficient to earn a single reinforcer
during the session.
Drug Administration
Test compounds were administered acutely to determine their effects on food
maintained responding under a FR10 schedule. A FR10 schedule was implemented in order to
best maintain the rats’ target body weight percentage because some animals were earning
more nutritive food pellets under the FR1 schedule during the session than their daily food
ration would allow. Administration of i.p. minocycline (0, 10, 30, 60 mg/kg) 67 minutes prior or
i.p. buspirone (0, 1, 3, 10 mg/kg) was given 30 minutes prior to the test session. Minocycline’s
effects on differential reinforcing baselines of food-maintained behavior was examined given its
effects on the previous self-administration studies as well as it’s known reduction of other
stimulant-induced behavioral outcomes (Zhang et al., 2006; Chen et al., 2009a; Fujita et al.,
2012). Buspirone, a partial 5-HT1A agonist with some dopaminergic antagonist activity, is an
approved for treatment of anxiety. Buspirone was examined in the present study due to its
ability to attenuate other psychostimulant-induced behaviors such as self-administration and reinstatement (Gold & Balster, 1992; Bergman et al., 2013; Shelton et al., 2013). Furthermore,
the literature remains unclear as to whether buspirone significantly affects food-maintained
behavior because significant rate decreasing were observed in a drug discrimination paradigm
under buspirone treatment (Ator, 1991) but no significant decrease was observed in a selfadministration procedure (Bergman et al., 2013). Thus, buspirone provided a test compound
which may or may not have significant effects on food-maintained behavior and significantly
affected drug abuse-related behaviors. Between all test sessions with either minocycline or
buspirone, rats were required to meet stability criteria on a FR10 schedule before moving to the
next dose.
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Preliminary results suggested that while statistically significant, 85 and 100% BW
conditions displayed a narrow window in demand between which to see differential effects of
drug on food-maintained responding. Thus, widening the window between the initial demand
conditions was hypothesized to allow for a better evaluation of differential drug effects. Thus,
buspirone rats’ percent body weight was increased to 115%, and they were re-tested under two
intermediate doses of buspirone (1.3 and 1.8 mg/kg).
Drugs
Minocycline hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in saline and a
few drops of 1 M hydrochloric acid. Immediately prior administration, the minocycline solution
was adjusted to pH 3-4 using a few drops of sodium hydroxide. Buspirone was dissolved in
saline. Minocycline and buspirone were both administered i.p. in 1 ml/kg body weight volume,
except for 60 mg/kg minocycline that was given at 2 ml/kg body weight volume due to
insolubility at the lower volume.
Data Analysis
Demand curves were generated using the formula log Q = log Q0 + k (e-αP – 1) from
Hursh and Silberberg (2008). Non-linear regression best fit values for the alpha level parameter
were compared between body weight conditions for each group (85%, 90%, 100%) or (85%,
100%, 115%) using an extra sum-of-squares F-test. When tested on a FR10 schedule, total
consumption of food pellets was normalized by calculating the percentage of reinforcer
consumption under test compound (minocycline or buspirone) treatment compared to total
consumption under vehicle conditions. Normalized consumption percentages were analyzed
using a two-way within subjects repeated measures ANOVA (repeated measures on treatment
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dose and body weight condition), and comparisons of minocycline and buspirone treatment on
consumption were assessed using Sidak’s Multiple Comparisons tests.

Results
The group α levels (95% CI) for each body weight condition (85%, 90%, 100%) were
calculated as 0.000041 (0.000036-0.000045), 0.000058 (0.000052-0.000064), 0.000081
(0.000071-0.000092), respectively and were significantly different from one another [F (2, 178)
= 35, p<0.0001] (Fig. 11). Responding by rats when maintained at 85% of their free-feeding
body weight had a significantly smaller α level and a less elastic demand curve compared to
animals maintained at 100% body weight [F(1,122)= 63, p<0.0001].
Figure 12 illustrates a significant main effect of minocycline on normalized consumption
of the FOOD pellet reinforcer as compared to FOOD consumption under vehicle conditions
[F(3,15)= 24.98, p<0.0001], however there was no main effect of body weight condition nor a
significant interaction between the two variables. Multiple comparisons revealed that 30 and 60
mg/kg minocycline significantly attenuated FOOD consumption when it was normalized to its
corresponding vehicle condition in both body weight conditions (p<0.05).
Similarly, there was a significant difference in α levels between body weights tested for
the buspirone group [F (2,173) = 108, p<0.0001] (Fig. 13). The α levels for 85%, 100%, and
115% body weight were 0.000051 (0.000044-0.000057), 0.00025 (0.00019-0.00031), 0.00014
(0.00011-0.00017), respectively. Buspirone (1, 3, 10 mg/kg) produced a significant main effect
on normalize FOOD consumption [(F (3, 36) = 26.20, p<0.0001], however there was no main
effect of body weight condition nor a significant interaction. Buspirone (10 mg/kg) significantly
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reduced FOOD consumption when it was normalized to its corresponding vehicle and body
weight conditions (p<0.05) (Fig. 14).
Buspirone at 1.3 and 1.8 mg/kg produced a significant main effect [F (2, 8) = 14.33 p=
0.0023] on normalized FOOD consumption, while there was no main effect of body weight
condition when consumption was compared between animals maintained at 85% and 115% of
their free-feeding body weight. Multiple comparisons analyses revealed that 1.8 mg/kg
buspirone significantly attenuated FOOD consumption in both body weight conditions when
normalized to its appropriate vehicle treated condition (p<0.05) (Fig. 15).
Summary
Given the results obtained from the methamphetamine self-administration studies,
ibudilast, AV1013, and minocycline were all examined for their specificity of effect on
methamphetamine-maintained relative to behavior maintained by a non-drug reinforcer, banana
pellets. A behavioral economics analysis was applied to assess the baseline strengths
maintained by methamphetamine and banana pellet delivery. This approach was based on the
assumption that the most legitimate comparison of the effects of test drugs on
methamphetamine-specific behavior would be obtained when baseline strengths of food and
methamphetamine reinforcement were at similar levels. A follow-up study was conducted to
demonstrate "proof of concept" that baseline strength can be a determinant of whether or not an
effect by a challenge drug occurs. The baseline strengths utilizing the same reinforcer, food
pellets, were altered by manipulating the percentage of the free feeding body weight of the
subjects. Then, test compounds (minocycline and buspirone) were evaluated for their effects on
food-maintained responding at differing levels of baseline strength. The results obtained
indicated that there were not differential drug effects as a function of baseline strength under the
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conditions tested. However, there are several considerations of this study that limit the
conclusions that can be drawn from it that are discussed in the Discussion.
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Chapter III: Figure Legends
Fig. 3. Effects of ibudilast or its vehicle on group mean infusions of methamphetamine (0.001,
0.03, and 0.1 mg/kg/inf) obtained during daily 2-h self-administration sessions. Ibudilast was
administered at 1, 7.5, or 10 mg/kg i.p. b.i.d. for three consecutive days at each
methamphetamine self-administered dose. Data points represent the group means of total
infusions obtained during the third day of testing at each ibudilast dose. Bars through symbols
indicate ±S.E.M. Data point above “S” on the abscissa indicates results when saline was selfadministered when ibudilast's vehicle was given b.i.d. N=4 rats. *p<0.05 with respect to
infusions obtained under ibudilast's vehicle condition.

Fig. 4. Response Rate Dependency analysis of effects of 10 mg/kg ibudilast on
methamphetamine (0.03 mg/kg/inf or 0.1 mg/kg/inf) response rates when response rates were
approximately matched under vehicle conditions. Under ibudilast’s vehicle conditions the
response rate maintained by 0.1 mg/kg/inf methamphetamine were altered by increasing the FR
requirement (FR2-4). Ibudilast (10 mg/kg) was administered i.p. b.i.d. for three consecutive
days. Data represent the group means (±S.E.M.) of response rate maintained by both
methamphetamine infusion doses. N=4 rats. *p<0.05 with respect to response rate obtained
under ibudilast’s vehicle condition.

Fig. 5. Effects of AV1013 or its vehicle on group mean infusions of methamphetamine (0.001,
0.03, and 0.1 mg/kg/inf) obtained during daily 2-h self-administration sessions. AV1013 was
administered at 1, 10, or 30 mg/kg i.p. b.i.d. for three consecutive days at each
methamphetamine self-administered dose. Data points represent the group means of total
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infusions obtained during the third day of testing at each AV1013 dose. Bars through symbols
indicate ±S.E.M. Data point above “S” on the abscissa indicates results when saline was selfadministered when AV1013s vehicle was given b.i.d. N=5 rats. *p<0.05 with respect to infusions
obtained under AV1013s vehicle condition.

Fig. 6. Effects of minocycline or its vehicle on group mean infusions of methamphetamine
(0.001, 0.03, and 0.1 mg/kg/inf) obtained during daily 2-h self-administration sessions.
Minocycline was administered at 10, 30, or 60 mg/kg i.p once daily for three consecutive days at
each methamphetamine self-administered dose. Data points represent the group means of total
infusions obtained during the third day of testing at each minocycline dose. Bars through
symbols indicate ±S.E.M. Data point above “S” on the abscissa indicates results when saline
was self-administered when minocycline's vehicle (saline) was given daily. N=5 rats. *p<0.05
with respect to infusions obtained under minocycline's vehicle condition.

Fig. 7. Total demand for 0.1, 0.03 mg/kg/inf methamphetamine and banana pellets when rats
were maintained at 85% of their free-feeding body weight. Methamphetamine demand was
generated during daily 2-h self-administration session and banana pellet demand was
generated during daily 15-min sessions. Data points represent the group means of total log of
consumption of the reinforcing commodity (methamphetamine or banana pellets) as a function
of unit price (FR value). Brackets through the symbols indicate ±S.E.M. Solid line curves
represent the best non-linear fits for each reinforcer. N=5-6 rats.

Fig. 8. Effects of ibudilast (10mg/kg) on normalized consumption of 0.03 mg/kg/inf
methamphetamine self-administration and banana pellets under a FR1 schedule. Data were
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collected during daily 2-h methamphetamine self-administration sessions or daily 15-min
banana pellet sessions. Ibudilast (vehicle or 10 mg/kg) was administered i.p. b.i.d. for three
consecutive days 1-h before testing. Bars represent group means of normalized consumption
of either reinforcer obtained on the third day of testing ±S.E.M. N=4-5 rats. *p<0.05 with
respect to normalized consumption of either reinforcer under vehicle conditions.

Fig. 9. Effects of AV1013 (10, 30 mg/kg) on normalized consumption of 0.03 mg/kg/inf
methamphetamine self-administration and banana pellets under a FR1 schedule. Data were
collected during daily 2-h methamphetamine self-administration sessions or daily 15-min
banana pellet sessions. AV1013 (vehicle, 10, 30 mg/kg) was administered i.p. b.i.d. for three
consecutive days 1-h before testing. Bars represent group means of normalized consumption
of either reinforcer obtained on the third day of testing. Brackets through bars represent ±S.E.M.
N=3-5 rats. *p<0.05 with respect to normalized consumption of either reinforcer under vehicle
conditions.

Fig. 10. Effects of minocycline (10, 30, 60 mg/kg) on normalized consumption of 0.03 mg/kg/inf
methamphetamine self-administration and banana pellets under a FR1 schedule. Data were
collected during daily 2-h methamphetamine self-administration sessions or daily 15-min
banana pellet sessions. Minocycline (vehicle, 10, 30, 60 mg/kg) was administered i.p. once daily
for three consecutive days 67-min before testing. Bars represent group means of normalized
consumption of either reinforcer obtained on the third day of testing. Brackets through bars
represent ±S.E.M. N=5 rats. *p<0.05 with respect to normalized consumption of either
reinforcer under vehicle conditions.
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Fig. 11. Total demand for 45 mg nutritive FOOD pellets when rats were maintained at 85%,
90%, and 100% of their individual free-feeding body weight. FOOD pellet demand was
generated during daily 15-min sessions. As a within subject study, all animals were assessed
under all three body weight conditions. Data points represent the group means of total log of
consumption of the reinforcing commodity (FOOD) as a function of unit price (FR value).
Brackets through the symbols indicate ±S.E.M. Solid line curves represent the best non-linear
fits for each body weight condition. N=5 rats.

Fig. 12. Effects of minocycline (10, 30, 60 mg/kg) on normalized consumption of FOOD pellets
under a FR10 schedule. Total consumption under minocycline treatment was normalized to
total consumption of FOOD pellets following vehicle administration for each body weight
condition. Data was collected during daily 15-min sessions. Data points represent the group
mean of total normalized consumption as a function of minocycline dose in both body weight
conditions. Brackets through symbols represent ±S.E.M. N=6 rats. * and # indicate p<0.05 with
respect to normalized consumption of FOOD under vehicle conditions at 100% and 85% BW,
respectively.

Fig. 13. Total demand for 45 mg nutritive FOOD pellets when rats were maintained at 85%,
100%, and 115% of their individual free-feeding body weight. FOOD pellet demand was
generated during daily 15-min sessions. As a within subject study, all animals were assessed
under all three body weight conditions. Data points represent the group means of total log of
consumption of the reinforcing commodity (FOOD) as a function of unit price (FR value).
Brackets through the symbols indicate ±S.E.M. Solid line curves represent the best non-linear
fits for each body weight condition. N=5 rats.
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Fig. 14. Effects of buspirone (1, 3, 10 mg/kg) on normalized consumption of FOOD pellets
under a FR10 schedule. Total consumption under buspirone treatment was normalized to total
consumption of FOOD pellets following vehicle administration for each body weight condition.
Data were collected during daily 15-min sessions. Data points represent the group mean of
total normalized consumption as a function of buspirone dose in two body weight conditions
(85% and 100%). Brackets through symbols represent ±S.E.M. N=13 rats. * and # indicate
p<0.05 with respect to normalized consumption of FOOD under vehicle conditions at 100% and
85% BW, respectively.

Fig. 15. Effects of buspirone (1.3, 1.8 mg/kg) on normalized consumption of FOOD pellets
under a FR10 schedule. Total consumption under buspirone treatment was normalized to total
consumption of FOOD pellets following vehicle administration for each body weight condition.
Data was collected during daily 15-min sessions. Data points represent the group mean of total
normalized consumption as a function of buspirone dose in two body weight conditions (85%
and 115%). Brackets through symbols represent ±S.E.M. N=5 rats. * and # indicate p<0.05
with respect to normalized consumption of FOOD under vehicle conditions at 115% and 85%
BW, respectively.
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Chapter IV: Ibudilast’s effects on methamphetamine drug discrimination in the rat

Introduction
The purpose of the final research aim of this dissertation was to determine whether the
discriminative stimuli produced by methamphetamine administration are attenuated by ibudilast
administration. Others have reported that the PDE inhibitors, rolipram and nefiracetam,
significantly attenuate methamphetamine (0.2 and 0.5 mg/kg) drug discrimination in rats (Yan et
al., 2004; Yan et al., 2006). Given that we have shown ibudilast, which exhibits PDE inhibitory
activity, significantly attenuates methamphetamine-induced locomotor activity, sensitization, and
self-administration (above), ibudilast was hypothesized to significantly attenuate
methamphetamine’s discriminative stimulus effects.

Methods
Subjects
Ten adult male Long-Evans hooded rats (Harlan, Indianapolis, IN) were allowed to
acclimate to the vivarium for at least one week before training began. When not in testing, rats
were individually housed in standard plastic rodent cages in a temperature-controlled (22°C),
Association for the AAALAC International-accredited facility in which they had ad libitum access
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to water. Rats were allowed ad libitum rat chow (7012 Teklad LM-485 Mouse/Rat Sterilizable
Diet, Harlan Laboratories, Inc., Indianapolis, IN) for at least ten days in order to calculate each
individual’s free feeding body weight. Individual body weights were determined by averaging
daily weights from six consecutive days of ad libitum feeding prior to initiation of weight
maintenance and test sessions Rats were then maintained at 85% of their free-feeding body
weight by controlled feedings of rat chow after daily sessions and once daily over the weekend.
All rats were maintained on a reversed, 12 h/12 h light-dark cycle (0600-1800 h lights off) for the
duration of the experiment, and they were trained and tested during the dark segment of this
cycle. All procedures were carried out in accordance with the “Guide for the Care and Use of
Laboratory Animals” (Institute of Laboratory Animal Resources, National Academy Press, 1996)
and were approved by the Institutional Animal Care and Use Committee of Virginia
Commonwealth University.
Apparatus
Commercially-obtained test chambers equipped with two retractable levers, a 5-w
houselight, a Sonalert tone generator, and a food pellet dispenser (MED Associates, Inc., St.
Albans, VT) were used. Recording of lever presses and food dispenser activation was
accomplished by a microcomputer, interface, and associated software (MED-PCs IV, MED
Associates, Inc., St. Albans, VT).
Procedure
Discrimination Training
Rats were initially trained to lever press for 45 mg rodent purified diet dustless precision
pellet (BioServ, Frenchtown, NJ) delivery according to a FR10 schedule during daily 15-min
sessions (Mon-Fri). Five rats were trained to respond on the left lever and five rats on the right
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lever for food pellet delivery. This initially active lever eventually became the vehicle-designated
lever. Rats were then trained to respond on the opposite lever for food pellet delivery under a
FR10 schedule, which eventually became the drug-designated lever. During training sessions,
either 1 mg/kg methamphetamine or saline i.p. injection was administered 15 min pre-session
and the appropriately paired lever produced food pellets under a FR10 schedule. Training
sessions occurred using the following sequence which renewed bi-monthly.
(1) D-V-V-D-V
V-D-D-V-D
V-D-V-D-V
D-V-D-V-D

(2) V-D-D-V-V
D-V-D-V-D
D-V-V-D-D
V-D-V-D-V

Acute Tues/Fri Discrimination Testing
Testing commenced once the rats met training criteria in which the first fixed ratio (FFR)
was completed on the appropriate lever during at least 8 out of 10 consecutive sessions, and
80% of total responses had been emitted on the appropriate lever during these 8 sessions. Test
sessions subsequently occurred if the FFR was correct on both the most recent
methamphetamine and saline training sessions, otherwise additional training sessions were
given. During test sessions, which occurred on Tuesdays and Fridays, responding at either
lever was reinforced according to a FR10 schedule. Initially, methamphetamine (0.1, 0.3, 0.56,
1, and 3 mg/kg) was tested to obtain a generalization curve for the training dose (1 mg/kg).
Methamphetamine dose testing order was randomized across subjects.
Cumulative Dosing Training
An objective during testing was to rapidly obtain a complete dose-effect curve for
methamphetamine at each ibudilast dose tested. To do so, training under cumulative dosing
conditions was necessary before testing could begin to ensure that the procedure produced a
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generalization curve similar to that obtained under acute dosing conditions. After the acute
dose-effect curve for methamphetamine was obtained, cumulative dosing pilot training sessions
began. The pilot training sessions consisted of five 3-min reinforcement periods each preceded
by 10-min TO periods during which the test chambers darkened and response levers retracted.
Having five, 3-min food-reinforcement components preceded by 10-min TO periods ensured
that total food pellet availability remained constant at 15 min (similar to preceding training and
testing conditions) and that overall session duration did not exceed methamphetamine’s
approximate elimination half-life of 70-min (Cho et al., 2001). During pilot sessions, subjects
were administered saline 10-min prior to the first 3-min reinforcement period, methamphetamine
(1 mg/kg) at the commencement of the first TO period, and sham injections at the
commencement of the TO periods prior to the remaining reinforcement components. During
each reinforcement component, only the lever associated with the most recent injection
produced food reinforcement under a FR10 schedule. Pilot sessions were utilized to allow the
subjects to acclimate to the multi-component, multi-injection procedure, and to determine that
the pre-session injections controlled consistent lever selection for the 55 min session.
Cumulative dosing training was complete if subjects completed the FFR on the correct lever and
>80% of responding was emitted on the correct lever during all five food reinforcement periods.
Following pilot sessions, regular training with continuous 15-min training sessions resumed until
testing criteria were again met (i.e., correct FFR during the most recent drug and vehicle training
sessions).
Cumulative Dosing Testing
Once a subject met testing criteria, training was suspended for two full days (Sat-Sun)
during which ibudilast was administered b.i.d (see below) and the cumulative dosing testdays
occurred on the subsequent days (Mon-Tues). Beginning b.i.d. ibudilast dosing two days prior to
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the test sessions maintained consistency with the previously described behavioral protocols.
Multiple treatments (i.e. b.i.d. dosing) prior to beginning and throughout testing are necessary to
obtain steady-state drug levels of ibudilast in various tissue compartments and to enable
minimally sufficient glial attenuation that relates to the onset of other effects (Ledeboer et al.,
2006; Hutchinson et al., 2009a; Beardsley et al., 2010). Furthermore, dosing over weekends
avoided disruption of regularly scheduled training sessions (Mon-Fri). Cumulative dosing
testdays consisted of five, 3-min food availability periods each but the first proceeded by 10-min
TO periods. A methamphetamine (0, 0.1, 0.3, 0.56, 1, 3 mg/kg) dose effect curve was obtained
by combining results from two testdays in which cumulative doses of 0 (saline), 0 (sham), 0.1,
0.56 and 1, and 0 (saline), 0 (sham), 0.3, 1, and 3 mg/kg were obtained (in which acute doses of
0 (saline), 0 (sham), .1, .46, and .44 mg/kg, and 0 (saline), 0 (sham), 0.3, 0.7, and 2 mg/kg were
administered).
Ibudilast (0, 1, 7.5, 10 mg/kg) was administered b.i.d. beginning two days prior to the test
days and 1-h prior to testing on both test days. Between Testdays, subjects returned to daily
acute dosing 15-min session training and were required to meet test criteria before advancing.
Tested ibudilast doses were randomized between individual rats.
Testing and Training Lower Methamphetamine Doses (1 mg/kg vs. 0.56 or 0.3 mg/kg)
The literature suggests that the training dose utilized during a drug discrimination
procedure can be a pivotal component of the assay. For example, progressively lowering a
PCP training dose produces marked decreases in the ED50 for stimulus generalization and
parallel leftward shifts of the dose response curves indicative of greater stimulus generalization
at lower training doses (Beardsley et al., 1987). Further, an antagonist can more readily disrupt
discrimination of a particular drug when trained at a low training dose (Picker et al., 1993). Yan
et al (2006) first trained animals to discriminate 0.5 mg/kg methamphetamine and tested PDE
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inhibitors’ effects under 0.2 mg/kg methamphetamine conditions. Thus, in order to better
compare ibudilast’s effects as a PDE inhibitor and glial cell modulator to rolipram and
nefiracetam’s effects on methamphetamine drug discrimination, the subjects were re-trained at
a lower methamphetamine training doses (0.56 and 0.3 mg/kg).
Animals were re-trained to discriminate 0.56 mg/kg methamphetamine using the
procedures described above that involved only a single injection prior to each 15-min session
until training criteria were again met. As a probe to determine if even the high dose of ibudilast
(10 mg/kg) would now have effects different from those following discrimination training at the 1
mg/kg dose, the effects of 10 mg/kg ibudilast were tested on discrimination performance. To do
so, training was suspended for two full days during which (10 mg/kg) ibudilast was administered
b.i.d and then ibudilast was administered 1-h prior to a 15-min 0.56 mg/kg methamphetamine
testing session on the third day. The results from the probe were compared to the %DLR for
0.56 mg/kg methamphetamine obtained during a non ibudilast pre-treated 15-min control test
session.
Following this initial probe, the group was divided in two. Five of the 10 animals
remained at the 0.56 mg/kg methamphetamine training dose and underwent the cumulative
dosing procedure in order to obtain a full dose response curve for the 0.56 mg/kg training dose
and determine whether there was a leftward shift of the curve and reduction of the ED50 for
methamphetamine generalization. Further, the cumulative dosing procedure allowed for the
potential to examine ibudilast’s effects on methamphetamine discrimination at all doses of
methamphetamine, not just the training dose (0.56 mg/kg methamphetamine). Second, to better
approximate the training and testing conditions previously reported to result in antagonism of
the methamphetamine discriminative stimulus by other PDE inhibitors (Yan et al., 2004; Yan et
al., 2006), the methamphetamine training dose was further decreased to 0.3 mg/kg for the
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remaining five animals. Subjects were re-trained, as before, and required to meet training and
testing criteria at the 0.3 mg/kg methamphetamine training dose. A methamphetamine dose
response curve (0, 0.1, 0.3, 0.56, 1, 3 mg/kg) was obtained using the acute Tues/Fri testing
procedure where dose order was randomized between subjects. The acute procedure was
utilized here because initial acquisition to the lower training dose took much longer and stability
of discrimination performance was unstable.
Drugs
(±)-Methamphetamine hydrochloride (National Institute on Drug Abuse, Rockville, MD)
was prepared in sterile 0.9% saline. Methamphetamine stock solutions were sterilized by
filtration through 0.2 mm filtration disks. Ibudilast (3-isobutyryl-2-isopropylpyrazolo [1, 5-a]
pyridine) was received as a gift from MediciNova, Inc. (San Diego, CA) and was dissolved in a
35% PEG400, 10%Cremophor® RH40 (BASF, Ludwigshafen, Germany) aqueous vehicle.
Ibudilast was administered i.p.in 1 ml/kg body weight volume.
Data Analysis
The percentage of methamphetamine-lever presses (%DLR) was calculated for each
subject by dividing the number of lever presses emitted upon the methamphetamine-designated
lever by the total number of presses emitted, and multiplying this quotient by 100. Individual
values of %DLR were then averaged (±SEM). Complete generalization to the
methamphetamine discriminative stimulus was inferred when %DLR ≥80%. If a rat failed to
make at least 10 lever presses during a test session, its data were excluded from calculations of
%DLR but were included for mean response rate determinations. This exclusion was made to
prevent near-zero rates of responding from disproportionately influencing estimates of %DLR.
ED50 values and their confidence intervals (CI) were calculated for %DLR and for reducing
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response rates after a log-dose transformation using a variable slope, nonlinear regression
analysis. Methamphetamine slopes with and without co-administration of the test drug were
then determined parallel or not using the F test, and if parallel, intercepts were determined equal
or not as a measure of potency. Average ED50s from each condition were analyzed using an
un-paired t-test (in comparing acute vs. cumulative dosing procedures) or a one-way ANOVA
with Dunnett’s multiple comparisons post hoc tests (in ibudilast treatment conditions). Response
rates were calculated for each drug condition by dividing the total number of lever presses
emitted during the session by the number of seconds in the acute 15-min session (900-sec) or
for each individual 3-min test bin during the cumulative testing procedure (180-sec). Calculated
response rates under acute Tues/Fri methamphetamine conditions were compared using a oneway ANOVA with Dunnett’s multiple comparison’s post hoc tests. Calculated response rates for
acute vs. cumulative dosing procedures and ibudilast treated conditions were analyzed with a
two-way ANOVA (repeated measures on methamphetamine dose and between dosing
procedure or ibudilast condition). Differences in response rates from saline vehicle conditions
and/or compared to PEG/crem veh response rates were assessed using Bonferroni post hoc
analyses. All statistical tests were conducted using commercial computer software (Prism5d for
Macintosh, GraphPad Software, Inc., San Diego, CA), and all types of comparisons were
considered statistically significant if p<0.05.

Results
The upper frame of Figure 15 shows the percentage of methamphetamine lever presses
obtained during acute Tues/Fri tests when the rats were trained to discriminate 1 mg/kg
methamphetamine from saline. Complete generalization (>80% DLR) occurred at 1 and 3 mg/kg
97

methamphetamine, while saline produced near-zero drug lever presses. The ED50 (CI)
obtained was 0.53 (0.46-0.58) mg/kg methamphetamine for occasioning the 1 mg/kg
methamphetamine stimulus. There were no statistically significant effects of methamphetamine
on response rates at any dose compared to vehicle conditions (Fig. 15; lower frame).
Results from the cumulative dosing discrimination procedure produced similar results in
that both 1 and 3 mg/kg produced complete generalization to the 1 mg/kg methamphetamine
training stimulus, while saline and sham injections produced near-zero %DLR (Fig. 16; upper
frame). The ED50 for methamphetamine to occasion its 1 mg/kg discriminative stimulus was
0.58 (0.51-0.65) mg/kg. There was a significant main effect of methamphetamine dose on
response rates [F (5, 35) = 5.326, p=0.001] and interaction between methamphetamine dose
and the dosing procedure used [F (5, 35) = 3.982, p=0.0058]. Bonferroni post hoc analyses
indicated that in the cumulative dosing procedure there was a significant decrease in response
rates at 3 mg/kg methamphetamine compared to the saline condition (p<0.05). There were no
significant differences in the ED50s for %DLR or for suppressing response rates (Fig. 16; lower
frame) between the acute Tues/Fri and the cumulative dosing procedures.
During cumulative doing testing, complete generalization occurred at 1 and 3 mg/kg
methamphetamine with near-zero %DLR following saline and sham injections under PEG/crem
vehicle, 7.5, and 10 mg/kg ibudilast pre-treatment conditions (Fig. 17; upper frame). Complete
generalization occurred at 3 mg/kg of methamphetamine; however 1 mg/kg methamphetamine
fell just short of full generalization with an average of 79 %DLR for methamphetamine under 1
mg/kg ibudilast pre-treatment conditions. The calculated ED50s (CI) were 0.49 (0.42-0.56),
0.711 (0.62-0.82), 0.49 (0.42-0.57), and 0.50 (0.37-0.67) mg/kg for occasioning the 1 mg/kg
methamphetamine training dose under PEG/crem vehicle, 1, 7.5, and 10 mg/kg ibudilast pretreatment conditions, respectively. Further, there were no significant differences in ED50s for
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occasioning the 1 mg/kg methamphetamine stimulus following any ibudilast pretreatment
condition compared to pretreatment with PEG/crem vehicle. Methamphetamine [F (6, 54) =
16.18, p<0.0001] and ibudilast [F (3, 27) =14.71, p<0.0001] both had a significant main effects
on response rates in the cumulative dosing procedure (Fig. 17; lower frame). The high dose of
methamphetamine (3 mg/kg) significantly depressed response rates compared to saline and
sham conditions regardless of ibudilast pre-treatment dose (p<0.05). Ibudilast (7.5 mg/kg) pretreatment significantly decreased response rates at all methamphetamine doses compared to
PEG/crem vehicle and 10 mg/kg ibudilast pre-treatment decreased response rates at all the
methamphetamine doses with the exception of the high dose of methamphetamine (3 mg/kg)
(p<0.05).
Figure 18 illustrates the %DLR for methamphetamine obtained when the training dose
was lowered to 0.56 mg/kg. Unlike results when trained at 1 mg/kg methamphetamine, lowering
the training dose to 0.56 mg/kg methamphetamine now resulted with 0.56 mg/kg
methamphetamine completely occasioning methamphetamine lever pressing. A probe (n=7) to
determine the effects of 10 mg/kg ibudilast pretreatment on methamphetamine discrimination at
the new training dose (0.56 mg/kg) indicated no significant attenuation in %DLR for
methamphetamine compared to non-treated control test sessions.
When the rats were sub-divided into groups of five, subjects whose training dose
remained at 0.56 mg/kg methamphetamine were tested under cumulative dosing conditions in
order to characterize a complete dose-effect curve. Under ibudilast's vehicle (PEG/crem) pretreatment conditions, methamphetamine produced increasingly more methamphetamine
appropriate responding with increasing cumulative dose, with complete generalization at 0.56, 1
and 3 mg/kg methamphetamine. Although ibudilast was planned to be tested under these
conditions, proceeding forward with these tests seemed unwarranted and were not conducted
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considering that 0.3 mg/kg methamphetamine elicited near zero methamphetamine appropriate
responding and the probe analysis indicated that 10 mg/kg ibudilast does not affect % DLR
even at 0.56 mg/kg methamphetamine.
The remaining five animals were re-trained to discriminate 0.3 mg/kg methamphetamine
from saline. Although the subjects reached both training and testing criteria, their discrimination
behavior was not consistently stable from week to week thus promoting the use of the acute
Tues/Fri testing procedure. For example, it took an average of 16 training days to complete the
methamphetamine dose response curve when animals were trained at 1 mg/kg. Conversely,
the same five animals required an average of 28.8 training days to complete the entire dose
response curve when trained at 0.3 mg/kg methamphetamine. Further, while the training dose
(0.3 mg/kg) produced full generalization, both 0.56 and 1 mg/kg methamphetamine failed to
produce greater than 80% of methamphetamine appropriate lever responding. Thus, these
inconsistencies in discrimination at 0.3 mg/kg precluded further testing with ibudilast or its
vehicle.

Summary
The results from drug discrimination tests indicated that when trained to discriminate 1
mg/kg methamphetamine, increasingly greater proportions of % DLR occurred. There was not
a significant difference in the ED50s for %DLR or response rates when tested under the acute
or in a two-day cumulative dosing procedure. When ibudilast was administered as a
pretreatment following drug discrimination training at 1 mg/kg methamphetamine, there were no
significant differences in ED50 for methamphetamine at any ibudilast dose tested. However, 7.5
and 10 mg/kg ibudilast significantly attenuated session response rates compared to vehicle
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conditions. These results suggest that ibudilast was ineffective at attenuating
methamphetamine’s discriminative stimulus effects following training at 1 mg/kg
methamphetamine.
When animals were re-trained to discriminate methamphetamine at lower doses, a
training dose of 0.56 mg/kg methamphetamine was still not affected by 10 mg/kg ibudilast.
Finally, training at the 0.3 mg/kg methamphetamine training dose resulted in inconsistent
discriminative performance, which was considered too unreliable to permit subsequent tests
with ibudilast.
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Table 4. Number of rats included in each condition based on session response criteria
Meth Dose
0.1 mg/kg
0.3 mg/kg
0.56 mg/kg
1 mg/kg
3 mg/kg

Meth Dose
0.1 mg/kg
0.3 mg/kg
0.56 mg/kg
1 mg/kg
3 mg/kg

Tues/Fri Acute Vs. Cumulative Dosing Procedure
Procedure
Tues/Fri Acute
Response Rate
Cumulative
Dosing
n=10
n=10
n=8
n=10
n=10
n=8
n=10
n=10
n=8
n=10
n=10
n=8
n=9
n=10
n=7
2-Day Cumulative Dosing Procedure
Ibudilast Dose (b.i.d.)
PEG/crem veh
n=10
n=10
n=10
n=10
n=7

1 mg/kg
n=10
n=9
n=10
n=10
n=8

7.5 mg/kg
n=10
n=10
n=8
n=9
n=9

Response Rate
n=8
n=8
n=8
n=8
n=8

Response
Rate
10 mg/kg
n=9
n=10
n=9
n=10
n=7

n=10
n=10
n=10
n=10
n=10

Methamphetamine Probe Analysis (0.56 mg/kg Training Dose)
Meth Dose
Treatment Condition
No Pre-treatment Response Rate
10 mg/kg
Response Rate
ibudilast
0.56 mg/kg
n=8
n=8
n=7
n=8
1 vs 0.56 mg/kg Training Dose Comparison (Cumulative Dosing)
PEG/crem veh
1 mg/kg Training
0.56 mg/kg Training
0.1 mg/kg
n=10
n=3
0.3 mg/kg
n=10
n=3
0.56 mg/kg
n=10
n=3
1 mg/kg
n=10
n=3
3 mg/kg
n=7
n=2
Meth Dose

1 vs 0.3 mg/kg Training Dose Comparison (Tues/Fri Acute Dosing)
Meth Dose
PEG/crem veh
1 mg/kg Training
0.3 mg/kg Training
0.1 mg/kg
n=10
n=5
0.3 mg/kg
n=10
n=5
0.56 mg/kg
n=10
n=5
1 mg/kg
n=10
n=5
3 mg/kg
n=9
n=5
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Chapter V: Figure Legends
Fig. 15. Upper Frame: Methamphetamine %DLR during acute Tues/Fri tests. Discrimination
sessions were 15-min in duration. Data points represent the group means of %DLR ± S.E.M. for
each dosing procedure. “S” indicates results with saline vehicle. “Sh” indicates results following
sham injections. See Table 4 for groups sizes for each methamphetamine dose. Lower Frame:
Response rates during acute dosing tests. Data points represent the group means of response
rates ± S.E.M. for each dosing procedure. Other details identical to those described in the upper
frame. N=10 rats.

Fig. 16. Upper Frame: Comparison of %DLR of methamphetamine between acute Tues/Fri
dosing and cumulative dosing tests. Acute Tues/Fri dosing sessions were 15-min in duration.
Cumulative dosing data are a compilation of two consecutive days of testing in which five 3-min
active reinforcement periods were separated by 10-min TO periods to allow for injections and
drug absorption. Data points represent the group means of %DLR ± S.E.M. for each dosing
procedure. “S” indicates discrimination of saline vehicle. See Table 4 for group sizes for each
methamphetamine dose. Lower Frame: Response rates between acute Tues/Fri dosing and
cumulative dosing tests. Data points represent the group means of response rates ± S.E.M. for
each dosing procedure. Other details identical to those described in the upper frame. *p<0.05
with respect to saline response rates. N=10 rats.

Fig. 17. Upper Frame: Ibudilast’s effects on %DLR of methamphetamine during cumulative
dosing tests. Cumulative dosing data are a compilation of two consecutive days of testing in
which five 3-min active reinforcement periods were separated by 10-min TO periods to allow for
injections and drug absorption. Data points represent the group means of %DLR ± S.E.M. for
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each dosing procedure. “S” indicates results with saline vehicle. “Sh” indicates results following
sham injections. See Table 4 for groups sizes for each ibudilast dose. Lower Frame: Ibudilast’s
effects on responses rate during cumulative dosing tests. Data points represent the group
means of response rates ± S.E.M. for each dosing procedure. Other details identical to those
described in the upper frame. *p<0.05 with respect to PEG/crem vehicle response rates.
#p<0.05 with respect to saline and sham condition response rates. N=10 rats.

Fig. 18. Ibudilast’s (10 mg/kg) effects on %DLR for methamphetamine training dose (0.56
mg/kg) tests. Filled circle points represent %DLR ± S.E.M. from Tues/Fri acute dosing
methamphetamine dosing procedure when the animals were trained to discriminate 1 mg/kg
methamphetamine from saline. The filled square represents %DLR ± S.E.M. of an acute dose
of methamphetamine (0.56 mg/kg) training dose. The filled triangle represents ibudilast (10
mg/kg) treatment effects on 0.56 mg/kg methamphetamine %DLR ± S.E.M. “S” indicates results
with saline vehicle. See Table 4 for group sizes for each condition.

Fig. 19. Comparison of 1 vs. 0.56 mg/kg methamphetamine training dose effects on %DLR of
methamphetamine during cumulative dose tests. Both curves generated following ibudilast’s
vehicle (PEG/crem) pre-treatment. Cumulative dosing data is a compilation of two consecutive
days of testing in which five 3-min active reinforcement periods were separated by 10-min TO
periods to allow for dosing and absorption. Data points represent the group means of %DLR ±
S.E.M. for each dosing procedure. “S” indicates results with saline vehicle. “Sh” indicates results
following sham injections. See Table 4 for groups sizes for each methamphetamine dose.
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Fig. 20. Comparison of 1 vs. 0.3 mg/kg methamphetamine training dose effects on %DLR of
methamphetamine during acute Tues/Fri test sessions. Acute Tues/Fri sessions were 15-min in
duration. Data points represent the group means of %DLR ± S.E.M. for each dosing procedure.
“S” indicates results with saline vehicle. See Table 4 for group sizes for each methamphetamine
dose.
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Chapter V: DISCUSSION

Introduction
The evidence provided above suggests that modulating glial cell activity, and
consequently reducing glial cell associated neuroinflammation, and/or inhibiting PDE activity,
may modulate behaviors in animal models presumably predictive of clinical behavior associated
with drug abuse disorders. More specifically, the evidence suggests that attenuating microglial
and astrocyte activation and its subsequent inflammatory events elicited by methamphetamine
administration can reduce methamphetamine locomotor activity and sensitization, selfadministration, but perhaps not drug discrimination. Furthermore, given the control procedures
performed as a result of the self-administration study results, the data suggests that the glial
modulating compounds are not acting in a rate dependent manner, but may not be specific for
only reducing methamphetamine-specific behavior. Further studies are required in order to
determine whether the initial reinforcing efficacy of alternative reinforcers is important in
examining non-specific effects of potential pharmacotherapies.
Chapter II
Results from Chapter II indicated that ibudilast dose-dependently reduced the chronic
and acute effects of methamphetamine on locomotor activity in the mouse. Chronic treatment
with methamphetamine provided evidence of sensitization as subsequent administrations
elicited greater increases in distance traveled. The highest dose of ibudilast (13 mg/kg) tested
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significantly attenuated these methamphetamine-induced sensitization effects. Ibudilast's
analog, AV1013, which lacks its potency for inhibiting PDE, but retains its ability to suppress
activated glial activity, similarly dose-dependently attenuated methamphetamine's chronic and
acute locomotor activity effects, although it was ~ 6–9 fold less potent in doing so. These later
observations suggest that the ability to modulate glial activity is sufficient to attenuate
methamphetamine's locomotor activity effects, although PDE inhibition likely can additionally
contribute if present.
Ibudilast is a non-selective PDE inhibitor (Kishi et al., 2001; Gibson et al., 2006), glial cell
modulator and anti-inflammatory agent (Suzumura et al., 1999; Mizuno et al., 2004), and an
inhibitor of macrophage migration inhibitory factor (Cho et al., 2010). As such, its effects could
be a result of any or a combination of all these mechanisms. Some of these effects have
already been reported to reduce methamphetamine activity (see below). It is unlikely ibudilast’s
effects on methamphetamine are a result of directly affecting conventional mechanisms, for it
doesn't have effective activity at ~100 other radioligand binding and enzyme targets (Ledeboer
et al., 2006).
PDE inhibition, by itself, significantly reduces some methamphetamine behaviors. PDE
inhibitors, such as rolipram and nefiracetam, attenuate methamphetamine-induced locomotor
activity, sensitization, and the discriminative stimulus effects of methamphetamine (Iyo et al.,
1995; Iyo et al., 1996a; Iyo et al., 1996b; Mori et al., 2000; Yan et al., 2004; Yan et al., 2006).
Methamphetamine increases levels of cytokines and inflammatory factors, such as
tumor necrosis factor (TNFα), interleukin 6 (IL-6), interleukin 1β (IL-1β) mRNA levels, monocyte
chemo-attractant protein 1 (MCP-1), and intercellular adhesion molecule (ICAM-1) (Yamaguchi
et al., 1991; Nakajima et al., 2004b; Goncalves et al., 2008). Attenuation of glial cell activation
and pro-inflammatory signaling, and up-regulation of neuroprotective factors, activities of both
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ibudilast and AV1013, have also been reported to attenuate some of methamphetamine's
behavioral effects, including locomotor sensitization (Zhang et al., 2006; Niwa et al., 2007c).
Conversely, reducing GDNF levels potentiates methamphetamine self-administration and
reinstatement vulnerability (Yan et al., 2007). GDNF is a neurotrophic factor best known for its
role in cell survival and re-growth, especially in dopamine neurons, that has been recently
implicated negatively regulating drug abuse behaviors (Carnicella & Ron, 2009). Ibudilast’s antiinflammatory action reduces glial activation by suppressing TNFα, IL-6, IL-1β, MCP-1, and nitric
oxide (NO), while also increasing production of GDNF (Suzumura et al., 1999; Mizuno et al.,
2004). Although AV1013 lacks the efficacy of PDE inhibition of ibudilast, it has similar glial cell
modulatory activity (Cho et al., 2010). Both ibudilast and AV1013 reduce methamphetamineinduced locomotor behavior, suggesting that AV1013’s modulation of glial cell activation is
sufficient to attenuate methamphetamine effects.
Lilius (2009) reported that ibudilast could induce decreases in spontaneous locomotor
activity in rats following its acute administration. Although the Lilius study used rats, and the
present study used mice, the possibility of direct locomotor decreasing effects needs to be
considered in interpreting ibudilast's and AV1013's modulation of methamphetamine's locomotor
activity effects. It is unlikely that these potential locomotor decreasing effects could explain the
magnitude of their effects on methamphetamine's activity. Importantly, none of the dosage
regimens of ibudilast or AV1013 produced statistically significant reductions in locomotor activity
during either baseline test. Perhaps if there had been important locomotor decreasing effects of
these drugs initially, tolerance developed to them, for the drugs were given b.i.d beginning two
days prior to the initiation of testing, whereas in the Lilius study ibudilast was given acutely.
Additionally, acute tolerance may have occurred as well, for in the Lilius study, ibudilast was
administered 15 min before testing, whereas in the present study it was given one hour prior to
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locomotor tests, and sedative-like effects appear to wane within 30 min of its administration
(Ledeboer et al., 2006).
Both ibudilast and AV1013 attenuated methamphetamine-induced locomotor activity
when administered concurrently with methamphetamine. These results suggest that these drugs
potentially could blunt methamphetamine’s stimulatory effects or “value” to chronic users
potentially facilitating the effectiveness of other interventions such as psychotherapy.
Additionally, ibudilast and AV1013 significantly attenuated the hyperactivity effects following
acute methamphetamine challenge. Considering that limited re-exposure to an abused drug can
precipitate a longer-termed relapse in an abstinent abuser (Bigelow et al., 1977; Chornock et al.,
1992; de Wit, 1996), ibudilast and AV1013’s attenuation of an acute methamphetamine
challenge suggests usefulness as a relapse prevention treatment in abstinent abusers, which is
consistent with a previous report that ibudilast reduces reinstatement precipitated by
methamphetamine primes in rats previously reinforced with methamphetamine (Beardsley et al.,
2010). The possibility of clinically useful relapse prevention now extends to AV1013 as well.
The AD50 values for reducing the effects of the 3 mg/kg methamphetamine challenge
dose did not differ within ibudilast and AV1013 groups between the acutely and chronically
treated mice, suggesting that peak ability to blunt methamphetamine’s effects was reached by
two days of b.i.d. administration. This speculation requires the qualification that only a single
methamphetamine dose (3 mg/kg) was tested, and administration of these drugs was not given
for longer than seven days. Similarity between these AD50 values also suggests that tolerance
to their effectiveness did not develop, a desirable feature in a potential pharmacotherapeutic.
Several additional observations strengthen the interest in these drugs. In the present
study, repeated administration of methamphetamine-induced sensitization to its locomotor
activity effects was significantly attenuated by 13 mg/kg ibudilast. It has been suggested that
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sensitization plays a key role in drug addiction in humans (Sax & Strakowski, 2001; Chen et al.,
2009b). For example, three doses of d-amphetamine given to healthy human volunteers
produces significant increases in eye-blink and locomotor scores, as well as in reported mood
and subjective drug effects (i.e. euphoria) suggestive of sensitization (Strakowski & Sax, 1998).
In conjunction with the behavioral effects, the adaptations of specific brain regions implicated in
the process of sensitization have been associated with reward pathways linked to drug-seeking
and addiction (Robinson & Berridge, 1993). Thus, a compound that blunts sensitization may
have additional merit for consideration as a pharmacotherapy for drug abuse. Furthermore,
because the neurocircuitry, neurotransmitter, and neuronal receptor systems activated in
reinstatement models of drug abuse are similar to those systems involved in the process of
sensitization (Steketee & Kalivas, 2011), the potential usefulness of these drugs in treating
methamphetamine relapse is even further enhanced.
Summary
The present study identified that both ibudilast and its analog, AV1013, are able to
attenuate methamphetamine-induced locomotor activity in mice. Given AV1013's impotency to
affect PDE activity, these results suggest that glial cell modulation alone may be sufficient for
attenuating these methamphetamine effects. Treatments for stimulant abuse targeting
conventional mechanisms have generally proven unsuccessful. The present results are
consistent with others suggesting that modulating glial cell activity with drugs could provide a
novel, and perhaps fruitful target for treating methamphetamine abuse.
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Chapter III
Results from Chapter III reported that methamphetamine was established as a positive
reinforcer and was self-administered under vehicle pretreatment conditions characterized by an
inverted U-shaped curve relating infusion numbers to dose, with significantly more
methamphetamine infusions being obtained at the intermediate dose (0.03 mg/kg/inf) during
testing of all drugs, and at the highest dose (0.1 mg/kg/inf) during testing of ibudilast and
AV1013, relative to those obtained of saline. Ibudilast (10 mg/kg), AV1013 (10 and 30 mg/kg)
and minocycline (60 mg/kg) significantly reduced total 0.03 mg/kg/inf methamphetamine
infusions compared to vehicle pretreatment conditions. These results suggest that modulating
glial cell activity, and consequent neuroinflammatory processes, can modulate abuse-related
effects of methamphetamine.
All three compounds, ibudilast, AV1013, and minocycline; reduced infusion rates for 0.03
mg/kg methamphetamine self-administration. None of the test drugs increased infusion rates of
0.001 mg/kg/inf, the lowest tested dose of methamphetamine and dose that was not selfadministered under vehicle conditions. These observations suggest that the infusion-rate
reducing effects of these drugs at the 0.03 mg/kg/inf dose of methamphetamine was not
attributable to the test drugs "enhancing" the effects 0.03 mg/kg/inf methamphetamine to be
functionally experienced as a higher dose (and thus, advancing it along the descending limb of
the dose-effect curve). Instead, the data suggest that the effects promoting methamphetamine
self-administration were diminished at 0.03 mg/kg/inf by the test compounds. None of the
compounds, however, affected infusions maintained by the highest self-administered
methamphetamine dose (0.1 mg/kg/inf). There are several possible levels of explanation for the
lack of effect on 0.1 mg/kg/inf methamphetamine-maintained behavior, the first being at the
neurochemical level. Methamphetamine’s effects on glial cell activation and induction of pro116

inflammatory signals have been well established (Yamaguchi et al., 1991; Nakajima et al.,
2004b; Goncalves et al., 2008). Additionally, methamphetamine’s glial cell activation is
associated with changes in behavior (Miguel-Hidalgo, 2009). In the present study, rats selfadministered methamphetamine at an average of 3.7-4.5 mg/kg/2-h session when given access
to the 0.1 mg/kg/inf dose, and an average of 2.74-3.2 mg/kg/2-h session methamphetamine at
the 0.03 mg/kg/inf dose. Self-administration of both doses are likely high enough to produce
pro-inflammatory conditions, as it has been shown that a single dose of 1 mg/kg
methamphetamine administered subcutaneously produces a significant enhancement of
cytokine and chemokine induction in mice (Loftis et al., 2011). However, perhaps 0.1 mg/kg/inf
methamphetamine produces a glial response "insurmountable" by the tested doses of ibudilast,
AV1013, or minocycline. For instance, as the dose of methamphetamine increases, it may
activate glial cells faster and promote more cytokine transcription to induce its
neuroinflammatory effects. Thomas et al. (2004a) noted that there was a dose-dependent effect
of methamphetamine on microglial activation in the mouse striatum. Thus, the test compounds
may not be effective against those processes recruited at higher doses.
Relative potency analysis revealed that ibudilast was ~6 times more potent than
AV1013, and ~13 times more potent than minocycline in reducing self-administration of
methamphetamine. These data are consistent with my previous report that ibudilast is ~4-7
more potent in reducing methamphetamine-induced hyperlocomotion in mice than AV1013
(Snider et al., 2012). These findings also support that while glial cell modulation is sufficient to
attenuate some methamphetamine-induced behaviors, ibudilast’s PDE inhibition activity may
have acted in combination with glial suppression.
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Summary
The present study established methamphetamine self-administration at levels likely
great enough to induce glial activation and pro-inflammatory signaling. Ibudilast, AV1013, and
minocycline, three compounds that attenuate glial activity, all reduced self-administration of 0.03
mg/kg/inf methamphetamine. While the mechanism of these effects has yet to be definitively
identified, the previously published data and the present report, strengthen the linkage between
glial cell activation, neuroinflammation, and the behavioral effects of abused drugs.
Clarifying Ibudilast's Behavioral Mechanism of Action and Defining the Limits of its
Effectiveness
Ibudilast attenuated rates of self-administration at the self-administered dose of
methamphetamine that maintained the highest baseline response rate (0.03 mg/kg/infusion),
and did not significantly affect self-administration of another self-administered dose that
maintained a lower baseline rate (0.1 mg/kg/infusion). This raises the possibility that there was a
response-rate determinant of ibudilast's effectiveness. Also, although ibudilast was effective in
attenuating the locomotor activity and reinforcing effects of methamphetamine, it could not be
assumed that it would attenuate all effects of methamphetamine. Because of these two
observations, tests were conducted to determine if ibudilast's effects on methamphetamine selfadministration were attributable to response rate determinants, and other tests were conducted
to determine if its range of effectiveness and specificity in attenuating methamphetamine's
effects.
A possible behavioral mechanism for the effectiveness of ibudilast for reducing 0.03
mg/kg/inf but not 0.1 mg/kg/inf methamphetamine self-administration may be attributable to a
rate dependent effect. Dews (1955) reported that a dose of pentobarbital that increases low
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reinforced rates of responding can also decrease high rates of responding. Thus, a drug’s effect
on behavior can be a function of the baseline response rate. In the present study, total
responses (and infusions) emitted during the sessions in which responding was maintained by
0.03 mg/kg/inf methamphetamine were greater than that maintained by 0.1 mg/kg/inf
methamphetamine. Thus, it may be argued that the pre-treatment compounds differentially
affected responding because baseline responding (i.e. total responses and infusions obtained
under vehicle-treatment conditions) differed between methamphetamine doses to start.
However, this explanation is unlikely because when response rates were specifically matched in
rats maintained by 0.03 and 0.1 mg/kg/inf methamphetamine during Rate Dependency Analysis
tests, 10 mg/kg ibudilast still did not reduce response rates for 0.1 mg/kg/inf methamphetamine.
Furthermore, the response rate reductions at 0.03 mg/kg/inf methamphetamine were not likely a
result of non-specific behavioral suppression because total infusions (and consequently,
response rate) following pretreatment with ibudilast did not differ from baseline rates at either
the lowest or highest tested methamphetamine doses in the present study (and they would have
been if there was non-specific behavioral suppression) nor did ibudilast or AV1013 significantly
suppress locomotor activity in mice when tested alone under similar dosage regimens (Snider et
al., 2012). Ibudilast has been reported, however, to produce transient sedation and decreased
reactivity to touch in the Irwin test in Wistar (Han) rats (Ledeboer et al., 2006).
In observing the effectiveness of ibudilast reducing methamphetamine selfadministration, the question emerges regarding the degree to which ibudilast's effectiveness is
restricted to methamphetamine-maintained responding. Considering that ibudilast is a PDE
inhibitor with likely broad-ranging effects, and that its modulation of glial activity could also have
broad-ranging down-stream effects, ibudilast is unlikely to be solely specific in affecting
methamphetamine-maintained as opposed to other reinforcer-maintained responding. It is
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important, if only from a drug developmental view, to begin to characterize the range of
reinforced behavior ibudilast can affect. Given these considerations, the effects of ibudilast on
banana pellet maintained-behavior were examined. It was hypothesized that the baseline
strength of behavior (i.e., the efficacy of the reinforcer) could determine whether or not ibudilast
reduced responding. This was somewhat suggested by the observation that ibudilast reduced
responding maintained by 0.03 mg/kg/inf methamphetamine, and not at the higher dose of 0.1
mg/kg/inf, and often the higher the dose of a self-administered drug, the greater the reinforcing
efficacy (Griffiths et al., 1979). To ensure similar baseline strengths of banana- and
methamphetamine-maintained responding, a behavioral economic approach was used to help
equate them. The baseline reinforcing strength (α level) of both non-nutritive banana flavored
cellulose pellets (banana pellets) and methamphetamine self-administration were successfully
equated. The baseline reinforcing strengths of these two commodities were generated while
both reinforcers were controlled within closed economies.
When tested on a FR1 schedule, all compounds that significantly attenuated 0.03
mg/kg/inf methamphetamine-maintained responding also attenuated banana pellet
consumption, with the exception of 10 mg/kg AV1013. These findings possibly suggest that an
intermediate dose of AV1013 may be the best potential pharmacotherapeutic as it is the most
selective for methamphetamine-induced behaviors without affecting non-drug-maintained
behavior. The initial hypothesis asserted that none of the test compounds would alter foodmaintained behavior because banana pellet consumption does not inherently induce glial cell
activation and neuroinflammatory activity. There are at least two opposing conclusions that
could be drawn from the gathered results. First, all three test compounds affected both
methamphetamine and food maintained behavior, thus glial cell attenuation could reduce
behavior maintained by many reinforcer types through a similar mechanism. Mild chronic food
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restriction (85% body weight restriction), however, does not cause glial cell activation; in fact,
chronic food restriction attenuates age-related astrocyte and microglial activity (Morgan et al.,
1999). Hence, it is likely that the test compounds are not attenuating a banana pellet-induced
inflammatory action to reduce reinforcer-maintained behavior. Furthermore, while the animals
used for this study had a history of methamphetamine self-administration and abstinent human
methamphetamine abusers show protracted microglial activation (Sekine et al., 2008), the
activation is negatively correlated with time of abstinence (Sekine et al., 2008) and can return to
baseline levels in rodent subjects in as little as seven days (Thomas et al., 2004c).
A second conclusion that could be drawn from the behavioral economic study results is
that all three of the test compounds are exhibiting non-specific effects in which all behavior is
suppressed. As discussed above, while there was no significant effect on locomotor activity in
mice by ibudilast or AV1013, ibudilast (7.5 and 10 mg/kg) did significantly suppress response
rates for food pellet delivery in the drug discrimination studies. Minocycline (56 mg/kg) causes
locomotor activity suppression at 100 mg/kg i.p. (Kofman et al., 1990) and suppresses response
rates for food pellet reinforcer delivery in a drug discrimination paradigm but response rates are
only moderately affected by 32 mg/kg minocycline (Munzar et al., 2002). Symptoms such as
light-headedness, headaches and nausea have all also been reported as side effects of high
doses of minocycline in humans (Gump et al., 1977). However, disentangling the relationship
between methamphetamine’s, or any drug’s, specific effects on drug maintained behavior and
those of “non-specificity” is complex at best. The importance of determining this specificity
should be based on the usefulness of the drug’s outcome as a potential pharmacotherapeutic.
If a particular compound reduces drug self-administration by anesthetizing the animal,
disentangling that relationship is a vital component to determine for the progression of that
compound as a therapeutic tool. However, there are commonly prescribed
121

pharmacotherapeutics that engender non-specific effects (i.e. side effects). For example,
methadone is a widely utilized pharmacotherapeutic agent that has been used to help treat
opiate dependence for almost 50 years (Dole & Nyswander, 1965). Methadone maintenance
treatment also significantly suppresses food intake in rhesus monkeys, in fact with greater
specificity than it suppresses heroin self-administration (Mello et al., 1983). Thus, it may be
argued that suppression of food intake does not necessarily eliminate a compound from
consideration as a potential therapy, but rather adds important information to its
pharmacological profile to be considered in future studies.

Can Baseline Strength Determine Sensitivity to a Drug's Effect
To evaluate the assumption that a drug would differentially affect reinforced behavior
when differential baseline strengths were involved, 45 mg food pellets were used as the
reinforcer when subjects were maintained at three different body weight conditions (85, 90 and
100% BW). Initial food pellet reinforcer demand curves indicated that the α level for food when
maintained at 85% BW produced significantly more demand than when animals were
maintained at 90% and 100% BW, indicating that the baseline strength (reinforcing efficacy of
food pellets) at 85% was significantly stronger. When minocycline (30 & 60 mg/kg) was
administered, there was a significant decrease in total consumption of food compared to
vehicle, however there was no significant effect of body weight condition. Likewise, 10 mg/kg
buspirone produced similar results in significantly decreasing total consumption of food
independent of body weight condition.
The differences between the α levels obtained at 85, 90%, and 100% BW conditions
during the initial reinforcing strength assessment, while statistically significant, displayed a
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narrow window in demand between which to see differential effects of drug on food-maintained
responding. Thus, widening the window between the initial demand conditions was
hypothesized to allow for a better evaluation of differential drug effects. When animals’ percent
body weight was increased to 115%, they were re-tested under two intermediate doses of
buspirone. Again, while the demand for food between the 85% and 115% body weight
conditions was statistically different, there was no main effect of body weight condition under
buspirone treatment. The possibility of being below threshold for detecting differences under
these conditions remains a plausible possibility, however. Any attempt at widening the range
between α values by manipulation of body weight was precluded by concerns of maintaining the
animals’ health. A more thorough evaluation of the possibility that baseline strength can be a
determinant of the sensitivity to a drug's effect (while having a broad range between α values)
should involve reinforcers not directly essential for health, although this would likely necessitate
specialized reinforcer delivery equipment that was not available during the present tests.
General Conclusions
While seemingly intuitive to assess the effects of test compounds on responding
maintained by a non-drug reinforcer (i.e. non-nutritive banana pellets) in this manner, the
limitations of using banana pellets as a reinforcer may preclude further analyses using this
approach. For example, animals were observed to respond for but not necessarily eat all
earned banana pellets during a given session, even while maintained at 85% of their freefeeding body weight. Thus, it could be argued that the animals’ responding was maintained by
conditioned reinforcers other than the banana pellet delivery. However, the purpose of
generating α levels for methamphetamine and banana pellet maintained responding was to
approximate the baseline strength of responding for two distinct reinforcers. Whether those
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reinforcers were the primary reinforcers themselves (i.e. methamphetamine or banana pellets)
or conditioned stimuli does not matter. Baseline strengths for methamphetamine and banana
pellet maintained responding were also matched under incongruent experimental stimuli (i.e.
active lever, lights, tones), to reduce the probability conditioned stimuli from a
methamphetamine self-administration history would confound response strengths. Actual
consumption of the banana pellets was inconsequential to the question posed. The test
compounds were still assessed against two different reinforcer types while they were
maintained under similar reinforcing strength regardless of what unconditioned or conditioned
stimuli the animals were responding to or as a result of.
Secondly, while differences between α levels for pellet delivery at different body weights
was significantly different in tests with nutritive food-pellets as the reinforcer, the range of α
levels was relatively tight perhaps limiting detection of differential drug effects. Widening the
differences in initial baseline strength would require further food restriction and/or a pre-feeding
procedure that might compromise the health of the animals or add confounding variables.
An assessment of any test compounds’ effects on food maintained behavior is still a
valuable addition to basic information surrounding a potential pharmacotherapy. Thus, as an
alternative approach, food (or food-like) reinforcers may be examined concurrently with
methamphetamine in a choice procedure. Test compounds could then be assessed for their
ability to re-allocate methamphetamine maintained responding to food maintained responding.
For example, when cocaine and food are concurrently available, administration of monoamine
releaser compounds produce right-ward shifts in the cocaine choice dose response curve
(Negus, 2003; Banks et al., 2011) indicating a reduction in cocaine maintained behavior when
food is also available. This approach could be developed by first determining whether the two
reinforcers in question interact with one another before posing the choice. Those interactions, in
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behavioral economic terms could include two commodities acting as complements, substitutes
or independents.
Behavioral economics provides ways for describing interactions between two reinforcers
such as drug and food in choice procedures (Hursh, 1978; Elsmore et al., 1980; Bickel et al.,
1995). Two reinforcers available concurrently may act as substitutes, complements, or
independent reinforcers (Hursh, 1980; Hursh et al., 2005). The two reinforcers are considered
substitutes if consumption of commodity B increases with an increase in price of commodity A
(Hursh, 1980). Reinforcers are complements when consumption of commodity B decreases with
increases in the price of commodity A (Hursh, 1980; Hursh & Roma, 2013) indicating that one
reinforcer affects the reinforcing strength of the second reinforcer. Finally, the price of each
independent reinforcer has no effect on the consumption of the other (Hursh, 1980; Hursh &
Roma, 2013). In order to ascertain the specificity of a test compound on attenuating only
methamphetamine’s reinforcing strength, and not food, the two reinforcers would first need to be
matched in initial baseline strength and assessed as substitutes, complements, or independent
reinforcers in a behavioral economic paradigm. This would theoretically allow for an initial
baseline in which reinforcing strength is equated and interactions between the two commodities
are noted and controlled for. Then, administration of the test compounds during concurrent
choice of both reinforcers might elucidate whether the test compounds can re-allocate
responding to and from drug to food-maintained behavior and interactions of substitutes or
complement reinforcers does not confound a shift in choice.
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Chapter V
Rats trained to discriminate 1 mg/kg methamphetamine from saline emitted
progressively more methamphetamine-lever responses as methamphetamine dose increased
until at the training dose and above, nearly 100% of lever presses were emitted on the drugassociated lever. These results are consistent with previous reports of methamphetamine drug
discrimination in rats. Methamphetamine drug discrimination is well established, and
methamphetamine is known to substitute for other stimulants such as ephedrine, cocaine,
methylphenidate, d-amphetamine (Schechter, 1997b; Bondareva et al., 2002; Sevak et al.,
2009). Further, SKF77434 (a partial D1 agonist), SCH39166 (selective D1 antagonist),
varenicline (nicotinic agonist), pentobarbital, aripiprazole, and clomipramine (serotonin reuptake inhibitor) all attenuate methamphetamine or amphetamine drug discrimination (Tidey &
Bergman, 1998; Gatch et al., 2005; Lile et al., 2005; Desai & Bergman, 2010). Furthermore, and
most pertinent for the present studies, nefiracetam and rolipram, two PDE inhibitors, reduce
methamphetamine drug discrimination in rats (Yan et al., 2004; Yan et al., 2006). Given that
ibudilast also engenders PDE inhibitory activity, ibudilast was hypothesized to attenuate
methamphetamine’s discriminative stimulus properties.
While drug discrimination procedures conventionally utilize a single test drug
administration during test sessions (Brady & Balster, 1980), cumulative dosing procedures, in
which multiple administrations of test drug occur between periods of reinforcer availability within
a single test session, are also used (Walker & Young, 1993). Direct comparison of these two
types of procedures produce similar dose response relationships and ED50 values for drugpaired lever responding (Schechter, 1997a). Cumulative dosing testing procedures thus allows
for rapid data collection and flexibility between procedure types. Similarly, in the present study,
there were no significant differences between ED50s of methamphetamine generalization
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between the acute and cumulative dosing procedures. Thus, the cumulative dosing procedure
was utilized to assess ibudilast’s effects on methamphetamine drug discrimination.
Ibudilast did not significantly alter methamphetamine drug discrimination when the
animals were trained with 1 mg/kg methamphetamine. There are several possibilities for why
this might be the case including both neurochemical and behavioral explanations.
First, drug discrimination is proposed as a pre-clinical model for the subjective effects of
a drug (Schuster, 1976; Brady & Balster, 1981). The present study hypothesized that
methamphetamine’s glial and related neuroinflammatory effects are involved with
methamphetamine’s discriminative stimulus effects, and these stimulus effects could be
reduced by attenuating the associated glial effects with the chosen test compounds. Given the
present results, it remains possible that while methamphetamine-induced neuroinflammation
may be involved with some aspects of abuse-related behaviors, such as locomotor sensitization
and self-administration, it may not be involved with methamphetamine's discriminative stimulus
effects. The drug discrimination procedure can be used to determine the mechanism by which
drugs of abuse produce their interoceptive effects (Balster, 1990). Thus, perhaps the proposed
indirect neurochemical mechanism through which glial cell modulation affects
methamphetamine-induced behavior (see below) is separate from affecting interoceptive cues.
In addition to its glial cell modulatory and anti-inflammatory activity, ibudilast is also a nonselective PDE inhibitor for PDEs 3, 4, 10, and 11 (Kishi et al., 2001; Gibson et al., 2006).
Rolipram and nefiracetam, two selective PDE4 inhibitors, have been reported to attenuate
methamphetamine drug discrimination (Yan et al., 2006). While ibudilast is not more selective
for PDE4 over the others, it has relatively similar binding affinity to that of rolipram at all PDE4
isotypes (Gibson et al., 2006). Thus, ibudilast’s selectivity is likely not the reason it did not affect
methamphetamine discrimination while rolipram and nefiracetam were reported to do so.
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Behaviorally, previous literature has shown that it is plausible to have a disconnection in
effects between self-administration and drug discrimination involving the same compound
because the two procedures are measuring different pharmacological effects (Woolverton &
Balster, 1982). Experimenter-administrated test compounds, such as used in drug
discrimination procedures, compared to actively self-administered drug, such as in typical selfadministration procedures, can elicit different behavioral, neurochemical, and even proteomic
differences (Jacobs et al., 2003). Thus, these potential differences could explain the dissociation
between ibudilast significantly affecting self-administration yet not drug discrimination in the
present study. Finally, drug discrimination training and tests with ibudilast occurred using a 1
mg/kg methamphetamine training dose in the present study. However, the training dose utilized
during a drug discrimination procedure can be a pivotal component of the assay. For example,
progressively lowering a PCP training dose produces marked decreases in the ED50 for
stimulus generalization and parallel leftward shifts of the dose response curves indicative of
greater stimulus generalization at lower training doses (Beardsley et al., 1987). Further, an
antagonist can more readily disrupt discrimination of a particular drug when trained at a low
training dose (Picker et al., 1993). Yan et al (2006) trained animals to discriminate 0.5 mg/kg
methamphetamine and tested under 0.2 mg/kg methamphetamine conditions. Thus, in order to
better compare ibudilast's to rolipram and nefiracetam’s effects on methamphetamine drug
discrimination, the subjects were re-trained in the present study at lower methamphetamine
training doses (0.56 and 0.3 mg/kg).
Rats re-trained at 0.56 mg/kg methamphetamine were probed with 10 mg/kg ibudilast
pretreatment at the 0.56 training dose and there were no significant effects on discrimination.
Further analysis with the cumulative dosing procedure revealed that under ibudilast’s vehicle
conditions, the training dose was the lowest methamphetamine dose to completely occasion the
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0.56 mg/kg discriminative stimulus. Generating the entire dose response curve allowed for the
possibility that 0.3 mg/kg methamphetamine might produce partial generalization to the training
dose, in which case ibudilast would have been tested to determine if it could reduce
generalization. However, 0.3 mg/kg produced near zero methamphetamine appropriate lever
responding eliminating the opportunity to continue testing ibudilast under those conditions.
Finally, the remaining animals were retrained at 0.3 mg/kg methamphetamine. While the
animals eventually acquired the discrimination, performance during their training sessions were
not as stable or consistent as compared to when animals were trained at 1 mg/kg
methamphetamine. These findings are consistent with previous reports in that progressively
lower doses of a training dose increase the number of training sessions required to acquire the
discrimination and the number of errors occurring on training days following acquisition
(Beardsley et al., 1987). Generalization test results indicated that 0.56 and 1 mg/kg
methamphetamine, doses higher than the 0.3 mg/kg training dose, failed to produce full
generalization to the 0.3 mg/kg training stimulus, and this uncharacteristic result of well-trained
discriminative performance suspended enthusiasm to proceed with ibudilast testing.
In sum, ibudilast did not significantly affect methamphetamine generalization when
involving cumulative dosing procedures when rats were trained at 1 mg/kg methamphetamine,
or when tested with an acute dose of 0.56 mg/kg methamphetamine when animals were
retrained at 0.56 mg/kg. Stimulus control was not stable enough to warrant further testing with
animals trained at either 0.56 or 0.3 mg/kg.
Potential mechanisms connecting methamphetamine, PDE, inflammation, and behavior
How methamphetamine promotes neuroinflammation precisely is not yet known.
Reactive oxygen species, substance P, and dopamine quinones contribute to
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methamphetamine-induced cellular damage and apoptosis (Fleckenstein et al., 1997; Zhu et al.,
2006). As a result of the damaged cells and neurotoxicity, astrocytes and microglia become
activated and elicit an immune response and increase pro-inflammatory cytokine production
(Kita et al., 2008; Clark et al., 2012). While cell damage and death is a common catalyst for
inflammation induction, methamphetamine’s effects on inflammatory pathways can also
temporally occur before dopamine cell terminal pathology (LaVoie et al., 2004). Furthermore,
there is growing evidence that psychostimulants can activate both astrocytes and microglial
cells directly through a variety of mechanisms (Beardsley & Hauser, 2014). Thus,
methamphetamine-induced inflammation can occur at non-neurotoxic levels and independently
of cell damage. One mechanism that has been proposed for methamphetamine-induced
inflammation via the nuclear transcription factor kappa-light-chain-enhancer of activated B cells
(NF-κB) (Shah et al., 2012). Methamphetamine’s release of excitatory neurotransmitters
activates the metabotropic glutamate receptor, mGluR5. mGluR5 is described to activate the
intracellular signaling pathway, AKT/PI3K, that downstream induces the release of NF-κB,
which, in turn, translocates to the nucleus to promote transcription of inflammatory cytokine
proteins such as TNFα, IL-6 and IL-8 (Shah et al., 2012).
Bacterial lipopolysaccharide (LPS) is a gram-negative endotoxin that stimulates
inflammation via toll-like receptor-4 (TLR-4) (Chow et al., 1999). Methamphetamine and LPS
both induce inflammation through the AKT/PI3K pathways and induce NF-κB to translocate to
the nucleus and promote transcription of inflammatory cytokines (Ojaniemi et al., 2003; Shah et
al., 2012). Methamphetamine exacerbates LPS’s inflammatory signal (Liu et al., 2012a). These
effects are likely attributable to both compounds acting via NF-κB, MAPK, and AKT/PI3K
pathways (Liu et al., 2012a). Ibudilast and AV1013 antagonize macrophage migration inhibitory
factor (MIF) (Cho et al., 2010), a pro-inflammatory factor essential for TLR-4 function and
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inflammatory response (Roger et al., 2001). If LPS and methamphetamine’s inflammatory
signals are similar, ibudilast and AV1013’s antagonism of the TLR-4 receptor via modulation of
MIF may be one mechanism in which these compounds are reducing cytokine production and
inflammation. Furthermore, ibudilast reduces nuclear translocation of p65, a subunit of NF-κB,
potentially suggesting a mechanism for ibudilast’s reduction of MIF (El-Hage et al., 2014).
AV1013's minimal PDE inhibitory effects could contribute to its lower efficacy relative to ibudilast
in attenuating methamphetamine induced locomotor activity in mice and on-going selfadministration in rats. AV1013's lower efficacy in these assays could be due to reduced potency
at the drugs' glial targets. AV1013 is a less potent inhibitor of MIF with a Ki = 74.9 (± 8.5) μM
than is ibudilast, which has a Ki of 30.9 (± 2.8) μM (Cho et al., 2010). Given this, AV1013 may
be less effective in reducing methamphetamine activity due to a combination of decreased
potency at both PDE and glial targets. Interestingly, morphine’s inflammatory response occurs
when the glycoprotein, MD-2, forms a complex with TLR-4 and induces inflammation similar to
LPS (Wang et al., 2012a), thus providing evidence for ibudilast’s mechanism of action in
reducing opioid-induced inflammation and behavior as well.
Minocycline also inhibits pro-inflammatory action of microglia without affecting the antiinflammatory functionality of the cells (Kobayashi et al., 2013). Minocycline’s proposed
mechanism also includes interaction with LPS and the NF-κB pathway. Minocycline prevents
LPS induced degradation of Iκbα, an inhibitory factor, which ultimately prevents NF-κB
translocation to the nucleus and induction of inflammatory cytokine production (Nikodemova et
al., 2006). Minocycline also decreases binding of NF-κB to DNA which disrupts transcription
(Bernardino et al., 2009). Thus, all three test compounds are hypothesized to inhibit
inflammation and methamphetamine-induced behaviors via a similar neurochemical pathway.
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How attenuation of glial cell activation and neuroinflammatory activity translates into
modulating methamphetamine's behavioral effects is also unknown. However, stimulantactivated glial cells can respond, as a result, to influence the behavioral effects of the drug
(Beardsley & Hauser, 2014). One proposed mechanism involves the ability of glial cells to
regulate neurotransmission and synaptic strength by affecting the cell surface delivery and
retention of glutamatergic NMDA and AMPA receptors (Eroglu & Barres, 2010). Interestingly, an
up-regulation of TNFα, elicited from activated astrocytes, increases AMPA receptor expression
on the cell surface and increases NMDA and AMPA receptor-mediated synaptic currents
(Beattie et al., 2002; Stellwagen & Malenka, 2006) that improves synaptic efficacy. Conversely,
blockade of TNFα has the opposite effect (Beattie et al., 2002). Therefore, methamphetamineinduced increases in TNFα could indirectly increase the concentration of AMPA receptors and
their activation. In contrast, ibudilast and AV1013's attenuation of TNFα levels would inhibit
delivery of these receptors preventing signaling and synaptic change. Excessive activation of
both AMPA and metabotropic glutamate receptors may play a role in behavioral sensitization
and in the rewarding properties of stimulants such as cocaine and methamphetamine (Wolf,
1998). Thus, the blockade of these processes may be a link to suppressing the effects of
stimulant drugs.
What about PDE inhibition?
Increases in cAMP, by a PDE inhibitor like rolipram for example, reduce microglial
activation as well (Atkins et al., 2007). TNFα levels may also be affected via cAMP production,
which reduces further TNFα synthesis (Kast, 2000; Shames et al., 2001). Thus, under ibudilast
treatment, increasing cAMP and inhibiting TNFα synthesis both work to reduce further glial
activation. Consistently, elevations in inflammatory cytokines such as TNFα and IL1-β reduce
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the level of cAMP in microglia that can be reversed by PDE inhibition (Ghosh et al., 2012)
suggesting that PDE inhibition can be a potential therapeutic target even after the initial
inflammatory response has occurred.
Amphetamine derivatives, including methamphetamine and MDMA, have been identified
as agonists for an orphaned GPCR, the rat trace amine receptor (TAAR1), and work to upregulate cAMP release (Bunzow et al., 2001). TAAR1 is widely distributed and co-expresses
with both DAT and D2 receptors on DA neurons (Xie & Miller, 2007; Espinoza et al., 2011).
Cells incubated in 8-Bromo-cAMP mediated a PKA-dependent up-regulation in DAT uptake of
extracellular substrates (Batchelor & Schenk, 1998; Page et al., 2004) indicating cAMP’s
importance in DAT functionality. Further, MDMA was suggested to auto-inhibit dopaminergic
transmission via recruitment of TAAR1 (Di Cara et al., 2011) suggesting that TAAR1 is a
negative modulator of DAT (Xie & Miller, 2007). Interestingly, TAAR1 knockout mice exhibited
significantly more sensitization to amphetamine than wild type mice and TAAR1 decreased the
firing rate of DA neurons in the VTA suggesting that TAAR1 is also a negative modulator of the
behavioral effects of amphetamines (Lindemann et al., 2008). With ibudilast administration it
remains a possibility that an increase in cAMP, given its PDE inhibitory activity, might act to
recruit TAAR1 receptors to negatively modulate methamphetamine’s neurochemical and
behavioral effects. In sum, perhaps ibudilast's PDE inhibition and glial modulatory effects are
working in conjunction to produce the observed results.

Future Directions
Ibudilast and AV1013 are suggested to inhibit the p65 subunit of NF-κB which
subsequently inhibits its translocation to the nucleus and subsequent pro-inflammatory release
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(El-Hage et al., 2014). However, is there a molecular correlation between inflammatory activity
expression and behavior? The literature has suggested that a single bolus dose of 1 mg/kg
methamphetamine administered subcutaneously produces a significant enhancement of
cytokine and chemokine induction in mice (Loftis et al., 2011). If separated into individual
treatment groups, an important future direction would be to examine the ability of daily
methamphetamine self-administration to produce cytokine and chemokine induction, as well as
the ability of the test compounds ibudilast, AV1013, and minocycline to reduce that induction in
vivo. Further analysis of these hypotheses would include an examination of the molecular timecourse of methamphetamine’s induction of glial cell activation, the test compounds’ ability to
reduce it, and whether a tolerance to the immune reduction occurred following chronic
treatment.
In order to further clarify the range of behavior, beyond that modified by
methamphetamine, that these glial cell modulators attenuate it would be important to expand
upon the banana pellet and food-maintained behavior studies. The banana pellet studies
suggested that the test compounds do not just solely reduce methamphetamine-affected
behavior. The second control procedure attempted to examine drug effects on differential
reinforcer demand, however there were health-related and potentially behavioral limitations
using food reinforcement. An expansion of this line of study might include testing alternative
reinforcers when baseline reinforcing efficacy is matched to that of self-administration. For
example, would ibudilast attenuate a reinforcer that is not consumable such as intracranial selfstimulation (ICSS)? Another advantage to using ICSS would be the ability to differentially control
a wider range of baseline strengths of behavior by altering the frequency of stimulation.
Finally, in addition to the development of a potential pharmacotherapeutics for treating
drug-abuse behavior, there may also be some validity in exploring the possibility of alternative
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interventions such as healthy diet regimens to reduce inflammatory activity in the CNS. Thus,
would altering an abuser’s diet and nutrition be enough to reduce drug abuse behavior? The
literature suggests that dibenzocyclooctadiene lignans from the fruit of Schisandra wilsoniana, a
plant grown in Asia, attenuates agonist-induced action of the TLR2/4 receptor on microglia by
inhibiting MAPK and NF-κB pathways (Park et al., 2013). More readily recognizable foods
available in the US, including pomegranate (Rojanathammanee et al., 2013) onion, oregano,
and red sweet potato, also show the ability to reduce microglial activation even following
standardized “cooking” preparation (Gunawardena et al., 2014). Cinnamon and fresh ginger
also exhibit anti-inflammatory activity and attenuate microglial activation via the NF-κB pathway
(Ho et al., 2013a; Ho et al., 2013b). Thus, while an alteration in an addict’s diet may likely not
produce full abstinence, perhaps different types of nutrition programming used in conjunction
with behavioral and/or pharmacological therapies could be beneficial in sustaining abstinence
and reducing the risk of relapse.
Finally, the growing literature regarding the linkage between glial cell modulators
affecting stimulant abuse behavior has initiated the study of both ibudilast and minocycline in
clinical trials. Minocycline significantly reduced the “feel good drug effects” and “I feel high”
subjective ratings of d-amphetamine in an outpatient procedure using non-dependent healthy
volunteers (Sofuoglu et al., 2011). Furthermore, ibudilast is now in Phase IIb clinical trials to
assess its safety and efficacy in treatment seeking methamphetamine dependent volunteers
half of whom are also HIV positive. This trial will also be sufficiently powered to ascertain
whether ibudilast can significantly improve methamphetamine abstinence over the two-week
treatment period (Johnson & Iwaki, 2014).
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Conclusions
Methamphetamine’s induction of glial cell activation and neuroinflammatory activity
causes effects in the periphery, CNS, and on behavior. The present dissertation supports
evidence that there is a linkage between glial cell modulation and abuse-related behavior. The
glial cell modulators ibudilast and AV1013 were observed to significantly attenuate
methamphetamine-induced locomotor activity and sensitization in mice. In addition, ibudilast,
AV1013, and minocycline significantly attenuated methamphetamine self-administration in rats.
The range of abuse-related behavior that ibudilast could affect, however, had limits in that it did
not alter methamphetamine’s discriminative stimulus effects.
Each of these three assays illustrates a different component of drug abuse and thus all
three were important to assess as a collection. The results suggest that glial cell modulation
affects drug abuse-related behaviors associated with methamphetamine-induced hyperactivity,
sensitization and drug seeking, however they do not suggest a linkage with the subjective cues
of methamphetamine intoxication. Furthermore, studies utilizing a behavioral economics
approach indicated that these glial cell modulators may also affect behavior maintained by
alternative reinforcers, such as non-nutritive banana pellets, in which case further studies may
be warranted to assess the extent to which these compounds affect behavior maintained by
other reinforcers. In summary, compounds that modulate glial cell activation and
neuroinflammatory activity appear to be associated with some methamphetamine abuse-like
behaviors, and while there is more to understand regarding these mechanisms, compounds
such as those tested may provide novel targets for potential drug abuse pharmacotherapeutics.
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